10Q

0001393905-21-000010.txt : 20210114 0001393905-21-000010.hdr.sgml : 20210114 20210114170723 ACCESSION NUMBER: 0001393905-21-000010 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20201130 FILED AS OF DATE: 20210114 DATE AS OF CHANGE: 20210114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cell MedX Corp. CENTRAL INDEX KEY: 0001493712 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS RETAIL [5900] IRS NUMBER: 383939625 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54500 FILM NUMBER: 21529556 BUSINESS ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 BUSINESS PHONE: (844) 238-2692 MAIL ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 FORMER COMPANY: FORMER CONFORMED NAME: Sports Asylum, Inc. DATE OF NAME CHANGE: 20140324 FORMER COMPANY: FORMER CONFORMED NAME: Plandel Resources, Inc. DATE OF NAME CHANGE: 20100608 10-Q 1 cmxc_10q.htm QUARTERLY REPORT 10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2020

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Commission File Number: 000-54500

Cell MedX Corp.

(Exact name of registrant as specified in its charter)

Nevada		38-3939625
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

123 W. Nye Ln, Suite 446

Carson City, NV

89706

(Address of principal executive offices)

(Zip code)

(844) 238-2692

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ]		Smaller Reporting Company [X]
		Emerging Growth Company [ ]

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.) Yes [ ] No [X]

The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of January 14, 2020 was 59,388,564.

CONTENTS

PART I - FINANCIAL INFORMATION	1
Item 1. Financial Statements	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	2
Item 3. Quantitative and Qualitative Disclosure about Market Risk	7
Item 4. Controls and Procedures	7
PART II - OTHER INFORMATION	8
Item 1. Legal Proceedings	8
Item 1A. Risk Factors	8
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3. Defaults upon Senior Securities	11
Item 4. Mine Safety Disclosures	11
Item 5. Other Information	12
Item 6. Exhibits	12
SIGNATURES	14

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying unaudited condensed consolidated interim financial statements of Cell MedX Corp. as at November 30, 2020, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

Operating results for the three- and six-month periods ended November 30, 2020, are not necessarily indicative of the results that can be expected for the year ending May 31, 2021.

As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.

CELL MEDX CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(EXPRESSED IN US DOLLARS)

(Unaudited)

	November 30, 2020		May 31, 2020

ASSETS

Current assets
Cash	$	21,784	$	45,090
Inventory		53,051		51,886
Other current assets		20,748		60,367
Total current assets		95,583		157,343

Equipment		2,138		1,836
Total assets	$	97,721	$	159,179


LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	$	390,709	$	908,783
Accrued liabilities		10,350		34,565
Due to related parties		734,237		233,738
Notes and advances payable		646,173		502,437
Total liabilities		1,781,469		1,679,523

STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 300,000,000 shares authorized; 59,388,564 and 55,915,709 shares issued and outstanding at November 30, 2020 and at May 31, 2020, respectively		59,389		55,916
Additional paid-in capital		6,355,923		5,988,153
Obligation to issue shares		-		80,000
Reserves		366,493		366,493
Accumulated deficit		(8,440,058)		(8,049,520)
Accumulated other comprehensive income (loss)		(25,495)		38,614
Total stockholders' deficit		(1,683,748)		(1,520,344)
Total liabilities and stockholders’ deficit	$	97,721	$	159,179

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

F-1

CELL MEDX CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(EXPRESSED IN US DOLLARS)

(Unaudited)

	Three Months Ended November 30,				Six Months Ended November 30,
	2020		2019		2020		2019

Revenue
Sales	$	1,871	$	757	$	3,338	$	12,100
Distribution rights		-		9,480		-		18,438
Cost of goods sold		988		522		1,357		5,897
Gross margin		883		9,715		1,981		24,641

Operating expenses
Amortization		632		545		1,368		813
Consulting fees		62,447		61,728		139,387		150,999
Distribution expenses		-		19,173		261		35,620
General and administrative expenses		80,723		132,080		113,503		218,642
Research and development costs		38,538		95,894		123,675		156,607
Total operating expenses		182,340		309,420		378,194		562,681

Other items
Interest		(7,879)		(3,783)		(14,325)		(10,735)

Net loss		(189,336)		(303,488)		(390,538)		(548,775)

Foreign currency translation income (loss)		(7,227)		453		(64,109)		(6,488)
Comprehensive loss	$	(196,563)	$	(303,035)	$	(454,647)	$	(555,263)

Net loss per common share
Basic and diluted	$	(0.00)	$	(0.01)	$	(0.01)	$	(0.01)

Weighted average number of shares outstanding
Basic and diluted		59,388,564		55,075,636		58,054,426		51,139,321

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

F-2

CELL MEDX CORP.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(EXPRESSED IN US DOLLARS)

(Unaudited)

				Obligation		Additional						Accumulated Other
	Common Stock			to Issue		Paid-in				Deficit		Comprehensive
	Shares	Amount		Shares		Capital		Reserves		Accumulated		Income (Loss)		Total

Balance - May 31, 2019	44,282,749	$	44,283	$	-	$	5,109,866	$	14,400	$	(6,956,822)	$	15,714	$	(1,772,559)

Shares issued for cash	4,050,000		4,050		-		481,950		-		-		-		486,000
Shares issued on exercise of warrants	-		-		374,148		-		-		-		-		374,148
Net loss for the three months ended August 31, 2019	-		-		-		-		-		(245,287)		-		(245,287)
Translation to reporting currency	-		-		-		-		-		-		(6,941)		(6,941)

Balance – August 31, 2019	48,332,749	$	48,333	$	374,148	$	5,591,816	$	14,400	$	(7,202,109)	$	8,773	$	(1,164,639)

Shares issued on exercise of warrants	7,482,960		7,483		(374,148)		366,665		-		-		-		-
Net loss for the three months ended November 30, 2019	-		-		-		-		-		(303,488)		-		(303,488)
Translation to reporting currency	-		-		-		-		-		-		453		453

Balance - November 30, 2019	55,815,709	$	55,816	$	-	$	5,958,481	$	14,400	$	(7,505,597)	$	9,226	$	(1,467,674)

Balance - May 31, 2020	55,915,709	$	55,916	$	80,000	$	5,988,153	$	366,493	$	(8,049,520)	$	38,614	$	(1,520,344)

Shares issued for cash	988,000		988		(80,000)		246,012		-		-		-		167,000
Shares issued on exercise of options	2,484,855		2,485		-		121,758		-		-		-		124,243
Net loss for the three months ended August 31, 2020	-		-		-		-		-		(201,202)		-		(201,202)
Translation to reporting currency	-		-		-		-		-		-		(56,882)		(56,882)

Balance – August 31, 2020	59,388,564	$	59,389	$	-	$	6,355,923	$	366,493	$	(8,250,722)	$	(18,268)	$	(1,487,185)

Net loss for the three months ended November 30, 2020	-		-		-		-		-		(189,336)		-		(189,336)
Translation to reporting currency	-		-		-		-		-		-		(7,227)		(7,227)

Balance - November 30, 2020	59,388,564	$	59,389	$	-	$	6,355,923	$	366,493	$	(8,440,058)	$	(25,495)	$	(1,683,748)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

F-3

CELL MEDX CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(EXPRESSED IN US DOLLARS)

(Unaudited)

	Six Months Ended November 30,
	2020		2019

Cash flows used in operating activities
Net loss	$	(390,538)	$	(548,775)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable		14,325		10,735
Amortization		1,368		813
Unrealized foreign exchange		(48,686)		(2,909)
Non-cash IR fees		11,000		-
Changes in operating assets and liabilities
Inventory		2,070		(3,293)
Other current assets		29,937		11,849
Accounts payable		24,776		58,529
Accrued liabilities		(24,545)		2,823
Unearned revenue		-		(244)
Due to related parties		66,520		(8,898)
Net cash used in operating activities		(313,773)		(479,370)

Cash flows used in investing activities
Acquisition of equipment		(1,574)		(2,463)
Net cash used in investing activities		(1,574)		(2,463)

Cash flows from financing activities
Advances payable		-		15,000
Proceeds from notes payable		125,773		197,650
Proceeds from subscription to shares		167,000		486,000
Net cash provided by financing activities		292,773		698,650

Effects of foreign currency exchange on cash		(732)		1,002
Increase (decrease) in cash		(23,306)		217,819
Cash, beginning		45,090		57,172
Cash, ending	$	21,784	$	274,991

Non-cash financing transactions:
Exercise of warrants for debt	$	-	$	374,148
Exercise of options for debt	$	124,243	$	-

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

F-4

CELL MEDX CORP.

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

NOVEMBER 30, 2020

(Unaudited)

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness.

Unaudited Interim Financial Statements

The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2020, included in the Company’s Annual Report on Form 10-K, filed with the SEC on September 15, 2020. The interim unaudited condensed consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three- and six-month periods ended November 30, 2020, are not necessarily indicative of the results that may be expected for the year ending May 31, 2021.

Going concern

The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2020, the Company has not achieved profitable operations and has accumulated a deficit of $8,440,058. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.

Risks related to the rapid expansion of the COVID-19 pandemic

The Company is cognizant of the rapid expansion of the COVID-19 pandemic and the resulting global implications. To date, the Company has experienced minor disruptions to the Company’s day-to-day operations associated with delayed services resulting from various COVID-19 restrictions and shortage of man power experienced by some of the Company’s service providers. The Company cautions that there continues to be a possibility for increase of the restrictions currently in place, or addition of new restrictions currently not known to the Company. The impact of these restrictions on the Company’s operations, if implemented, is currently unknown but could be significant.

F-5

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than advances and notes payable to related parties (Note 7) at November 30, 2020, and at May 31, 2020:

	November 30, 2020		May 31, 2020
Due to the Chief Executive Officer (“CEO”)	$	109,200	$	103,200
Due to the Chief Financial Officer (“CFO”)		7,966		9,533
Due to/(from) the Vice President (“VP”), Technology and Operations		(3,424)		34,219
Due to a company controlled by the Chief Operating Officer (“COO”)⁽¹⁾		618,122		n/a
Due to a major shareholder		-		86,786
Due to a company controlled by the COO and major shareholder		2,250		n/a
Due to a company of which the COO is a director of		123		n/a
Due to related parties	$	734,237	$	233,738

(1)John da Costa was appointed Director and Chief Operating Officer of the Company on June 8, 2020, as of that date any company controlled by Mr. Da Costa is considered to be a related entity.

The amounts due to related parties are unsecured, due on demand and bear no interest.

During the six-month periods ended November 30, 2020 and 2019, the Company had the following transactions with related parties:

	November 30, 2020		November 30, 2019
Management fees incurred to the CEO	$	6,000	$	21,600
Management fees incurred to the CFO		13,500		6,000
Consulting fees incurred to the VP, Technology and Operations		22,337		22,593
Consulting fees incurred to the company controlled by the COO		77,378		n/a
Royalty incurred to the company of which the COO is a director of		53		n/a
Total transactions with related parties	$	119,268	$	50,193

NOTE 3 - INVENTORY

As at November 30, 2020, the inventory consisted of eBalance® devices and accessories held for sale valued at $29,290 (May 31, 2020 - $29,405) and work in progress, that included unfinished eBalance® devices and supplies required for manufacturing valued at $23,761 (May 31, 2020 - $22,481).

NOTE 4 - OTHER CURRENT ASSETS

As at November 30, 2020, other current assets consisted of $14,325 in prepaid expenses (May 31, 2020 - $44,021) and $6,423 in receivables associated with GST Cell MedX Canada paid on taxable supplies (May 31, 2020 - $16,346).

NOTE 5 - EQUIPMENT

Changes in the net book value of the equipment at November 30, 2020 and May 31, 2020 are as follows:

	November 30, 2020		May 31, 2020
Book value, beginning of the period	$	1,836	$	1,281
Changes during the period		1,574		2,463
Amortization		(1,368)		(1,846)
Foreign exchange		96		(62)
Book value, end of the period	$	2,138	$	1,836

F-6

NOTE 6 - REVENUE

During the six-month period ended November 30, 2020, the Company’s revenue consisted of monthly subscriptions to eBalance® microcurrent treatments. During the comparative six-month period ended November 30, 2019, the Company’s revenue consisted of sales of its eBalance® devices, and the fees associated with the rights to the wholesale distribution of eBalance® devices pursuant to a letter of intent the Company entered into on June 6, 2019, which granted a potential distributor rights to all Mainland China, not including Hong Kong. Following are the details of revenue and associated costs:

	Three months ended November 30,				Six months ended November 30,
	2020		2019		2020		2019
Sales of eBalance^® devices	$	-	$	757	$	-	$	12,100
Monthly subscriptions		1,871		-		3,338		-
Cost of eBalance^® devices and services		(958)		(434)		(1,304)		(4,485)
Royalty payable		(30)		(88)		(53)		(1,412)
Distribution rights		-		9,480		-		18,438
Gross margin	$	883	$	9,715	$	1,981	$	24,641

NOTE 7 - NOTES AND ADVANCES PAYABLE

The tables below summarize the short-term loans and advances outstanding as at November 30, 2020, and May 31, 2020:

As at November 30, 2020
Principal Outstanding		Interest Rate per Annum		Accrued Interest⁽⁶⁾		Total Book Value
$	327,650	6%	Convertible⁽¹⁾	$	21,039	$	348,689
	141,065	6%	Non-convertible⁽²⁾		5,942		147,007
	7,045	6%	Related party⁽³⁾		552		7,597
	35,606	6%	Related party⁽⁴⁾		2,789		38,395
	15,426	6%	Related party⁽³⁾		369		15,795
	40,440	0%	Related party advances⁽⁵⁾		-		40,440
	48,250	0%	Advances⁽⁵⁾		-		48,250
$	615,482			$	30,691	$	646,173

As at May 31, 2020
Principal Outstanding		Interest Rate per Annum		Accrued Interest⁽⁶⁾		Total Book Value
$	327,650	6%	Convertible⁽¹⁾	$	10,731	$	338,381
	28,630	6%	Non-convertible⁽²⁾		3,464		32,094
	6,625	6%	Related party⁽³⁾		308		6,933
	35,606	6%	Related party⁽⁴⁾		1,654		37,260
	87,769	0%	Advances⁽⁵⁾		-		87,769
$	486,280			$	16,157	$	502,437

(1) Convertible Loans Payable

During the year ended May 31, 2020, in order to support its daily operations and to secure required working capital, the Company entered into several short-term convertible loan agreements with two lenders for a total of $327,650 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly. Pursuant to the loan agreements, the lenders may convert any portion of principal and/or interest accrued thereon into restricted units of common stock in the capital of the Company on the terms and at a conversion price of the then-current private placement offering. The conversion rights were assessed to have $Nil value.

During the six-month period ended November 30, 2020, the Company recorded $10,308 in interest on the convertible loans payable (2020 - $2,668).

F-7

(2) Non-convertible Loans Payable

During the six-month period ended November 30, 2020, the Company entered into several short-term loan agreements with two lenders for a total of $111,000 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly. As at November 30, 2020, the Company owed a total of $147,007 (2020 - $32,094) under 6% unsecured loan agreements.

During the six-month period ended November 30, 2020, the Company recorded $2,303 in interest on these loans (2020 - $951).

(3) Related Party Loans Payable

As at November 30, 2020, the Company owed a total of $7,597 (2020 - $6,933) under unsecured loan agreement with Mr. Jeffs, the Company’s major shareholder. During the six-month period ended November 30, 2020, the Company recorded $219 in interest on the loan with Mr. Jeffs. (2020 - $2,425).

On July 9, 2020, the Company entered into a loan agreement for $14,773 (CAD$20,000) with a related party. The loan bears interest at 6% per annum compounded monthly, is unsecured, and payable from the first proceeds of warrants that may be exercised subsequent to the money being lent under the loan agreement or on July 9, 2021, whichever comes first. During the six-month period ended November 30, 2020, the Company recorded $360 in interest on the principal (2020 - $Nil).

(4) Unsecured Line of Credit with Related Party

On December 27, 2018, the Company entered into an agreement with Mr. Jeffs for an unsecured line of credit of up to $250,000 (the “Credit Line”). The funds advanced under the Credit Line accumulate interest at a rate of 6% per annum compounded monthly and are payable on demand. On August 28, 2019, Mr. Jeffs applied $250,000, the Company owed under the Credit Line to exercise the warrants the Company granted to Mr. Jeffs in consideration for the Credit Line and acquired 5,000,000 shares of the Company’s common stock at $0.05 per share.

As at November 30, 2020, the Company owed Mr. Jeffs $38,395 under the Credit Line (2020 - $37,260), which continues to accumulate interest at 6% per annum compounded monthly. During the six-month period ended November 30, 2020, the Company recorded $1,135 in interest on principal outstanding under the Credit Line (2020 - $4,691).

(5) Advances Payable

As at November 30, 2020, the Company owed a total of $88,690 (2020 - $87,769) for advances the Company received in its fiscal 2019 and 2020 years. The advances are non-interest bearing, unsecured, and payable on demand. Of the total amount advanced, $3,870 was owed to Da Costa Management Corp, a company owned by John da Costa, who was appointed the Company’s COO and Director on June 8, 2020 (2020 - $3,639), $11,570 (2020 - $10,880) was owed to Brek Technologies Inc., a company controlled by Mr. da Costa and Mr. Jeffs (Note 2), and $25,000 (2020 - $25,000) was owed to Mr. David Jeffs, the CEO and President of Live Current Media, Inc., of which Mr. da Costa is director of.

(6) Interest Expense

During the six-month period ended November 30, 2020, the Company recorded a total of $14,325 (2020 - $10,736) in interest expense associated with its liabilities under the notes and advances payable.

NOTE 8 - SHARE CAPITAL

On July 30, 2020, the Company issued 988,000 units of its common stock for gross proceeds of $247,000, of which $80,000 were received during the year ended May 31, 2020. Each unit consisted of one common share of the Company and one warrant allowing its holder to acquire an additional common share at $0.35 until January 30, 2021, and at $0.50 per share from January 30, 2021 to July 30, 2022.

On August 13, 2020, the Company issued 1,250,000 shares of its common stock to Ms. Arnett, the Company’s 10% shareholder, on the exercise of 1,250,000 options at $0.05 per option. Ms. Arnett chose to apply $62,500 the Company owed to her on account of past services against the exercise price of the shares. Ms. Arnett transferred the remaining $24,712 the Company owed to her as at August 13, 2020, to Mr. Hargreaves, the Company’s director of VP; Technology and Operations, in a private transaction.

F-8

On August 13, 2020, the Company issued 1,234,855 shares of its common stock to Mr. Hargreaves, the Company’s VP; Technology and Operations, on the exercise of 1,234,855 shares at $0.05 per option. Mr. Hargreaves chose to apply $61,743 the Company owed to him against the exercise price of the shares.

Options

The changes in the number of stock options outstanding during the six-month period ended November 30, 2020, and for the year ended May 31, 2020, are as follows:

	Six months ended November 30, 2020			Year ended May 31, 2020
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	7,050,000	$	0.24	7,050,000	$	0.24
Options exercised	(2,484,855)	$	0.05	-	$	n/a
Options expired	(1,015,145)	$	0.34	-	$	n/a
Options outstanding, ending	3,550,000	$	0.35	7,050,000	$	0.24

Details of options outstanding and exercisable as at November 30, 2020, are as follows:

Number of options outstanding and exercisable	Exercise price	Grant date	Expiry date
500,000	$0.35	August 5, 2015	January 1, 2021
500,000	$0.35	August 5, 2015	April 1, 2021
500,000	$0.35	August 5, 2015	July 1, 2021
2,050,000	$0.35	August 24, 2017	August 23, 2022
3,550,000	$0.35

At November 30, 2020, the weighted average remaining contractual life of the stock options outstanding was 1.14 years.

Warrants

The changes in the number of warrants outstanding during the six-month period ended November 30, 2020, and for the year ended May 31, 2020, are as follows:

	Six months ended November 30, 2020			Year ended May 31, 2020
	Number of warrants	Weighted average exercise price		Number of warrants	Weighted average exercise price
Warrants outstanding, beginning	18,864,605	$	0.94	20,297,565	$	0.78
Warrants issued	988,000	$	0.35/$0.50	6,050,000	$	0.38
Warrants exercised	-	$	n/a	(7,482,960)	$	0.05
Warrants expired	(1,480,000)	$	1.50	-	$	n/a
Warrants outstanding, ending	18,372,605	$	0.86	18,864,605	$	0.94

F-9

Details of warrants outstanding as at November 30, 2020, are as follows:

Number of warrants exercisable	Grant date	Exercise price
2,000,000	March 3, 2016	$0.75 expiring on March 3, 2021
9,094,605	October 12, 2016	$1.50 expiring on October 12, 2021
240,000	February 7, 2018	$1.50 expiring on February 7, 2021
3,950,000	June 24, 2019	$0.20 expiring on June 24, 2021
100,000	July 22, 2019	$0.20 expiring on July 22, 2021
1,000,000	January 29, 2020	$0.50 expiring on March 12, 2023
1,000,000	January 29, 2020	$1.00 expiring on March 12, 2023
988,000	July 30, 2020	$0.35 during the period from July 30, 2020 to January 30, 2021 $0.50 during the period from January 30, 2021 to July 30, 2022
18,372,605

At November 30, 2020, the weighted average life of the warrants was 0.86 years.

F-10

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report.

The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2020, filed with the United States Securities and Exchange Commission (the “SEC”) on September 15, 2020.

Overview

We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our new business direction. On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia.

We are a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health, pain relief, wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson’s disease, high blood pressure, neuropathy and kidney function. Our Subsidiary is engaged in development and manufacturing of therapeutic devices based on our proprietary eBalance® Technology, which harnesses power of microcurrents and their effects on human body.

Current uncertainty with respect to rapid expansion of the COVID-19 pandemic

We are cognizant of the rapid expansion of the COVID-19 pandemic and the resulting global implications. To date, we have experienced minor disruptions to our day-to-day operations associated with delayed services resulting from various COVID-19 restrictions and shortage of man power experienced by some of our service providers. We caution that there continues to be a possibility for increase of the restrictions currently in place, or addition of new restrictions currently not known to us. The impact of these restrictions on our operations, if implemented, is currently unknown but could be significant.

Update on eBalance® Research and Development Activities

At the end of February 2020, we completed an audit required for certification of our quality management systems (“QMS”) under Stage 2 Medical Device Single Audit Program (“MDSAP”) and under ISO 13485:2016 standard. The audit was carried out by BSI Group Canada Inc. (“BSI”) and included the following:

-The effectiveness of our QMS incorporating the applicable regulatory requirements outlined by ISO13485:2016 standard and as required under MDSAP;

-Product/process-related technologies;

-Adequate technical documentation for our eBalance® device in relation to ISO13485:2016 standard and MDSAP; and

-Our ability to comply with these requirements.

The assessment report was finalized in mid-March 2020, and on March 31, 2020, we received Certificate No. FM 716345, certifying that the Company operates a Quality Management System which complies with the requirements of ISO 13485:2016 for design, development and manufacture of microcurrent therapeutic devices for wellness and pain relief, and on June 2, 2020, received a certificate #MDSAP 716274.

Following the receipt of ISO and MDSAP certificates, we filed two separate applications for Class II Medical Device Licenses for the eBalance® Pro System and the eBalance® Home System with Health Canada. On July 17, 2020, Health Canada issued a Class II Medical Device License #104925 for our eBalance® Home System, and on August 18, 2020, issued a Class II Medical Device License #105044 for our eBalance® Pro System.

Prior to selling our eBalance® Home and Pro Systems for the treatment in the United States, we will be required to apply for an approval from the FDA. As of the date of this Quarterly Report on Form 10-Q we are in the process of completing the necessary documentation and testing required for the 510(K) submission to the FDA.

Extension of Investor Outreach Program with Think Ink Marketing

On September 23, 2020, we signed an extension agreement with Think Ink Marketing Data & Email Services, Inc. (“Think Ink”) to continue providing public relations services in an effort to increase public awareness of the Company and our products, services and securities. The agreement is for twelve months with either party having the right to terminate upon thirty-day notice.

Think Ink is a California-based marketing firm established in 1991 that provides its customers with a complete range of marketing services that span both digital and direct mail venues. The Company has budgeted up to $25,000 per month for the services of Think Ink including banner and native ads.

Results of Operations for the Three and Six Months ended November 30, 2020 and 2019

Our operating results for the three- and six-month periods ended November 30, 2020 and 2019, and the changes in the operating results between those periods are summarized in the table below.

	Three Months Ended					Six Months Ended
	November 30, 2020		November 30, 2019		Percentage Increase/ (Decrease)	November 30, 2020		November 30, 2019		Percentage Increase/ (Decrease)
Sales	$	1,871	$	757	147.2%	$	3,338	$	12,100	(72.4)%
Distribution rights		-		9,480	(100.0)%		-		18,438	(100.0)%
Cost of goods		(988)		(522)	89.3%		(1,357)		(5,897)	(77.0)%
Gross margin		883		9,715	(90.9)%		1,981		24,641	(92.0)%
Operating expenses
Amortization		632		545	16.0%		1,368		813	68.3%
Consulting fees		62,447		61,728	1.2%		139,387		150,999	(7.7)%
Distribution expenses		-		19,173	(100.0)%		261		35,620	(99.3)%
General and administrative expenses		80,723		132,080	(38.9)%		113,503		218,642	(48.1)%
Research and development costs		38,538		95,894	(59.8)%		123,675		156,607	(21.0)%
Total operating expenses		182,340		309,420	(41.1)%		378,194		562,681	(32.8)%
Interest		7,879		3,783	108.3%		14,325		10,735	33.4%
Net loss	$	189,336	$	303,488	(37.6)%	$	390,538	$	548,775	(28.8)%

Revenues

During the three-month period ended November 30, 2020, we recognized $1,871 in revenue, which consisted of monthly recurring revenue associated with the eBalance® treatment packages. The cost attributed to this revenue was $988.

During the three-month period ended November 30, 2019, we recognized $757 in revenue, which consisted of sales of our eBalance® wellness devices to end-users. The cost attributed to this revenue was $522.

During the six-month period ended November 30, 2020, we recognized $3,338 in revenue, which consisted of monthly recurring revenue associated with the eBalance® treatment packages. The cost attributed to this revenue was $1,357.

During the six-month period ended November 30, 2019, we recognized $12,100 in revenue, which consisted of sales of our eBalance® wellness devices to end-users. The cost attributed to this revenue was $5,897 and included $3,713 in manufacturing costs of eBalance® devices, and $1,412 in royalties we accrued on the sales.

On June 6, 2019, we entered into a letter of intent for the wholesale distribution rights to all Mainlined China, not including Hong Kong (the “LOI”). As part of the LOI the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000, of which $18,438 we recorded as revenue from distribution rights for the six-month period ended November 30, 2019 ($9,480 for the three-month period ended November 30, 2019). During the three- and six-month periods ended November 30, 2020, we did not generate any revenue from distribution rights.

As of the date of this Quarterly Report on Form 10-Q, we continue research and further development of our eBalance® Technology and devices based on this technology. During the summer of 2020, Health Canada granted our eBalance® Home and Pro Systems Class II medical device licenses, which allow us to market our eBalance® devices for wellness and pain management. Our certification with FDA continues to be ongoing; at the time of this Quarterly Report on Form 10-Q we are compiling required documentation for a 510(K) premarket submission, which allows us to demonstrate that the eBalance® device is at least as safe and effective as a legally marketed device available on the market. Once this submission is approved, it will allow us to start our commercial activity in the USA.

Operating Expenses

During the three-month period ended November 30, 2020, our operating expenses decreased by 41.1% from $309,420 we incurred during the three months ended November 30, 2019, to $182,340 we incurred during the three months ended November 30, 2020. The most significant expenses during this period included $51,319 in corporate communication fees (November 30, 2019 - $83,181), $38,538 we incurred in research and development fees (November 30, 2019 - $95,894), $62,447 in consulting fees (November 30, 2019 - $61,728), $5,012 in accounting and audit fees (November 30, 2019 - $15,925), and $10,500 in management fees (November 30, 2019 - $13,800). During the comparative three-month period ended November 30, 2019 we incurred $19,173 in distribution expenses paid or accrued to our sales representatives, expense that we did not incur in the current period.

On a year-to-date basis, the most significant changes were as follows:

·During the six-month period ended November 30, 2020, our consulting fees decreased by $11,612, or 7.7%, from $150,999 we incurred during the six-month period ended November 30, 2019, to $139,387 we incurred during the six-month period ended November 30, 2020. Larger consulting fees during the comparative period ended November 30, 2019, were associated with $25,000 we paid for consultation on setting up our distribution channels in China.

·Our research and development fees for the six-month period ended November 30, 2020, decreased by $32,932, or 21%, from $156,607 we incurred during the six-month period ended November 30, 2019, to $123,675 we incurred during the six-month period ended November 30, 2020. The lower research and development fees during the six-month period ended November 30, 2020, were associated with the conclusion of the work associated with Health Canada certifications, and reduced work load associated with our 510(K) submission to the FDA. In addition, we continued minor developments of the eBalance® systems.

·Our general and administrative fees for the six-month period ended November 30, 2020, decreased by $105,139, or 48.1%, from $218,642 we incurred during the six-month period ended November 30, 2019, to $113,503 we incurred during the six-month period ended November 30, 2020. The largest factor that contributed to this change was associated with fluctuation in foreign exchange rates, which, during the six-month period ended November 30, 2020, resulted in $47,167 gain, as compared to $540 gain during the comparative period; our expenditures on corporate communications decreased by $45,937 to $93,582 we recorded during the six-month period ended November 30, 2020, as compared to $139,519 we incurred during the six-month period ended November 30, 2019. Other factors that affected our general and administrative fees were associated with a $12,902 decrease to our accounting and audit fees, which decreased from $22,925 we incurred during the six-month period ended November 30, 2019, to $10,023 for the six-month period ended November 30, 2020. Our management fees decreased by $8,100 from $27,600 we incurred during the six-month period ended November 30, 2019 to $19,500 we incurred during the six-month period ended November 30, 2020, the decrease resulted from renegotiation of monthly management fees with the Company’s CEO and the CFO. In addition, during the current period, we incurred $1,227 in marketing and advertising fees as opposed to $5,785 we incurred during the six-month period ended November 30, 2019. These decreases were in part offset by $14,471 in professional fees which we incurred during the six-month period ended November 30, 2020, the expense we did not incur in the comparative period.

·During the six-month period ended November 30, 2020, we incurred $261 in distribution expenses we paid or accrued to our sales representatives (November 30, 2019 - $35,620). Based on our agreements with the sales representatives, we agreed to pay CAD$350 as commission for each eBalance® device they sell. In order to allow our sales representatives to establish their customer base, during the six-month period ended November 30, 2019, we were paying a monthly fee of CAD$5,000 to each sales representative. Due to a delay in securing Health Canada Class II device licenses, we suspended our agreements with sales representatives in January 2020. As of the date of this Quarterly Report on Form 10-Q we have suspended discussions on re-engagement of the sales representatives.

Other Items

During the three-month period ended November 30, 2020, we accrued $7,879 (November 30, 2019 - $3,783) in interest associated with the outstanding notes payable. On a year-to-date basis, we accrued $14,325 (November 30, 2019 - $10,735) in interest associated with the outstanding notes payable. Of this interest, $1,354 (November 30, 2019 - $7,095) represented interest we accrued on the notes payable we issued to Mr. Jeffs, our major shareholder.

Liquidity and Capital Resources

Working Capital

	As at November 30, 2020		As at May 31, 2020		Percentage Change
Current assets	$	95,583	$	157,343	(39.3)%
Current liabilities		1,781,469		1,679,523	6.1%
Working capital deficit	$	(1,685,886)	$	(1,522,180)	10.8%

As of November 30, 2020, we had a cash balance of $21,784, a working capital deficit of $1,685,886 and cash flows used in operations of $313,773 for the period then ended. During the six-month period ended November 30, 2020, we funded our operations with $167,000 received from our private placement financing, and $125,773 we borrowed under loan agreements accumulating interest at 6% per annum, compounded monthly, and due on demand.

We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the period ended November 30, 2020. The amount of cash we have generated from our operations to date is significantly less than our current debt obligations. There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under the outstanding notes and advances payable, or to service our other debt obligations. If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

Cash Flows

	Three months ended
	November 30, 2020		November 30, 2019
Cash flows used in operating activities	$	(313,773)	$	(479,370)
Cash flows used in investing activities		(1,574)		(2,463)
Cash flows provided by financing activities		292,773		698,650
Effects of foreign currency exchange on cash		(732)		1,002
Net increase (decrease) in cash during the period	$	(23,306)	$	217,819

Net Cash Used in Operating Activities

Net cash used in operating activities during the six months ended November 30, 2020, was $313,773. This cash was primarily used to cover our cash operating expenses of $412,531 and to decrease our accrued liabilities by $24,545. These uses of cash were offset by $66,520 increase in amounts due to related parties, $29,937 decrease in other current assets, $24,776 increase in our accounts payable, and by a $2,070 decrease in inventory.

Net cash used in operating activities during the six months ended November 30, 2019, was $479,370. This cash was primarily used to cover our cash operating expenses of $540,136, to increase our inventory by $3,293, and to decrease our unearned revenue and amounts due to related parties by $244 and $8,898, respectively. These uses of cash were offset by $11,849 decrease in other current assets, and by $58,529 and $2,823 increases in our accounts payable and accrued liabilities, respectively.

Non-cash transactions

During the six-month period ended November 30, 2020, our net loss was affected by the following expenses that did not have any impact on cash used in operations:

·$14,325 (2020 - $10,735) in interest we accrued on the outstanding notes payable. Of this interest, $1,354 (2020 - $7,095) was accrued on the notes payable we issued to Mr. Jeffs;

·$48,686 (2020 - $2,909) in unrealized foreign exchange gain, which resulted from fluctuations of Canadian dollar in relation to US dollar, our functional and reporting currencies;

·$1,368 (2020 - $813) in amortization of equipment we acquired for our manufacturing operations and for our office; and

·$11,000 (2020 - $Nil) in non-cash investor relations expenses which were associated with fair market value of the shares we issued to our consultant for investor relation services in April 2020.

Net Cash Used in Investing Activities

During the six-month period ended November 30, 2020, we purchased office equipment for $1,574 (2020 - $2,463).

Net Cash Provided by Financing Activities

During the six-month period ended November 30, 2020, we received $125,773 under loan agreements, which are payable on demand and accumulate interest at 6% per annum. In addition, we received $167,000 on closing of our non-brokered private placement for 988,000 units of our common stock at $0.25 per unit for total proceeds of $247,000, of which $80,000 was received during the year ended May 31, 2020. We did not incur any share-issuance costs associated with the units issued as part of the private placement financing.

During the six-month period ended November 30, 2019, we received $197,650 under convertible loan agreements, which are payable on demand and accumulate interest at 6% per annum. At discretion of the lenders, the full amount due under the loans can be converted into the units of our common stock at the then-current price of private placement financing. In addition, we received a total of $15,000 in non-interest-bearing advances which are payable on demand. In addition to the funds received as part of debt financing, we issued 4,050,000 units of our common stock for total proceeds of $486,000. We did not incur any share-issuance costs associated with the units issued as part of the private placement financing.

Going Concern

The notes to our unaudited condensed consolidated financial statements as at November 30, 2020, disclose our uncertain ability to continue as a going concern. Our current business operations are in an early development stage and as such, we were able to generate only minimal revenue from the operations. Our research and development as well as marketing plans for the near future will require large capital expenditures, which we are planning to mitigate through equity or debt financing, or by requiring upfront deposits from our potential distributors, once we begin commercial production of our eBalance® devices.

As at November 30, 2020, we had accumulated a deficit of $8,440,058 since inception and increased sales will be required to fund and support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our unaudited condensed consolidated interim financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.

Off-Balance Sheet Arrangements

None.

Critical Accounting Policies

An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.

Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure

None.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

None

Item 4. Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, 2020. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

During the quarter ended November 30, 2020, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There is a high degree of risk associated with investing in our securities. Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.

The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment. We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also impair or adversely affect our business, financial condition or results of operation.

Risks associated with the current uncertainty with respect to rapid expansion of the COVID-19 pandemic

Risks Associated with our Company and our Industry

We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments. Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.

The market for devices and therapies for treating and managing diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with large pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, MediSense Inc. and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.

We are subject to numerous governmental regulations which can increase our costs of developing our eBalance® Technology and products based on this technology.

Our products may be subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that we will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.

Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.

Competitors may claim that our Technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.

Our research and development efforts may not result in the development of commercially successful products based on our eBalance® Technology, which may hinder our profitability and future growth.

Our eBalance® Technology is currently in the research and development stage as are our planned products incorporating this technology. In order to develop commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make ongoing substantial expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.

Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations.

Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether our products under development will be launched, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.

New products and technological advances by our competitors may negatively affect our results of operations.

Our products face intense competition from our competitors. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.

Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.

Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.

Inability to attract and maintain key personnel may cause our business to fail.

Success depends on the acquisition of key personnel. We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants. If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.

To date we have generated only minimal revenues. If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.

To date we have generated only minimal revenues. No profits have been made to date and if we fail to make any then we may fail as a business and an investment in our common stock will be worth nothing. We have a very limited operating history and thus our progress as well as potential future success cannot be reasonably estimated. Success has yet to be proven and financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance® Technology, of which there is no assurance. We continue to face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties. Since inception, we have accumulated deficit of $8,440,058 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.

We need to acquire additional financing or our business will fail.

We must obtain additional capital or our business will fail. In order to continue development of our eBalance® Technology and to successfully carry out our planned clinical and observational trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on. We currently have no arrangements for additional financing. We may also have to borrow large sums of money that require substantial capital and interest payments.

Risks related to our stock

We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.

Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue. However, there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.

There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.

Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.

Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.

Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations. Liquidity may be low despite there being a market, making it difficult to get a return on the investment. The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.

Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.

Because our securities constitute "penny stocks" within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:

·contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;

·contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws;

·contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;

·contains a toll-free telephone number for inquiries on disciplinary actions;

·defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and

·contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.

We have not paid nor anticipate paying cash dividends on our common stock.

We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history. The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:

(a)we would not be able to pay our debts as they become due in the usual course of business; or

(b)except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution.

We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit
Number		Description of Document
3.1		Articles of Incorporation ⁽²⁾
3.2		Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.⁽³⁾
3.3		Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.⁽³⁾
3.4		Bylaws ⁽¹⁾
4.1		Specimen Stock Certificate ⁽¹⁾
10.1		Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.⁽⁴⁾
10.2		First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.⁽⁵⁾
10.3		Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.⁽⁶⁾
10.4		Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.⁽⁷⁾
10.5		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Yanika Silina⁽⁸⁾
10.6		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Da Costa Management Corp.⁽⁸⁾
10.7		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and John Giovanni Di Cicco.⁽⁸⁾
10.8		Intellectual Property Royalty Agreement between Cell MedX Corp. and Brek Technologies Inc., dated for reference September 6, 2018.⁽⁹⁾
10.9		Royalty Agreement between Cell MedX Corp. and Mr. Richard Norman Jeffs, dated for reference September 6, 2018.⁽⁹⁾
10.1 0		Credit Line Agreement dated December 27, 2018, between Richard Norman Jeffs and Cell MedX Corp.⁽¹⁰⁾
10.1 1		Distribution Agreement between Cell MedX Corp. and Live Current Media, Inc., dated for reference March 21, 2019. ⁽¹¹⁾
10.1 2		Loan Agreement and Note Payable dated September 4, 2019, among Cell MedX Corp. and Longview Investment Limited ⁽¹²⁾
10.1 3		Loan Agreement and Note Payable dated September 6, 2019, among Cell MedX Corp. and Rain Communications Corp. ⁽¹²⁾
10.1 4		Loan Agreement and Note Payable dated September 16, 2019, among Cell MedX Corp. and Longview Investment Limited⁽¹²⁾
10.1 5		Loan Agreement and Note Payable dated September 19, 2019, among Cell MedX Corp. and Rain Communications Corp. ⁽¹²⁾
10.1 6		Loan Agreement and Note Payable dated September 20, 2019, among Cell MedX Corp. and Longview Investment Limited⁽¹²⁾
10.1 7		Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Longview Investment Limited ⁽¹²⁾
10.1 8		Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Rain Communications Corp. ⁽¹²⁾
10.1 9		Loan Agreement and Note Payable dated December 3, 2019, among Cell MedX Corp. and Longview Investment Limited ⁽¹³⁾
10.2 0		Loan Agreement and Note Payable dated January 6, 2020, among Cell MedX Corp. and Longview Investment Limited⁽¹³⁾
10.2 1		Loan Agreement and Note Payable dated January 9, 2020, among Cell MedX Corp. and Longview Investment Limited⁽¹³⁾

Exhibit
Number		Description of Document
10.2 2		Loan Agreement and Note Payable dated January 31, 2020, among Cell MedX Corp. and Longview Investment Limited⁽¹³⁾
10.2 3		Buyback agreement between Live Current Media Inc. and Cell MedX Corp., dated January 29, 2020.⁽¹⁴⁾
10.2 4		Loan Agreement and Note Payable dated February 17, 2020, among Cell MedX Corp. and Longview Investment Limited⁽¹³⁾
10.2 5		Loan Agreement and Note Payable dated March 4, 2020, among Cell MedX Corp. and Longview Investment Limited⁽¹³⁾
10.2 6		Loan Agreement and Note Payable dated March 25, 2020, among Cell MedX Corp. and Longview Investment Limited⁽¹³⁾
10.2 7		Loan Agreement and Note Payable dated April 13, 2020, among Cell MedX Corp. and Longview Investment Limited⁽¹⁵⁾
10.2 8		Loan Agreement dated July 3, 2020, among Cell MedX Corp. and David Jeffs.⁽¹⁵⁾
10.29		Loan Agreement and Note Payable dated August 31, 2020, among Cell MedX Corp. and Tradex Capital Corp.⁽¹⁵⁾
10.3 0		Loan Agreement and Note Payable dated September 2, 2020, among Cell MedX Corp. and Rain Communications Corp.
10.3 1		Loan Agreement and Note Payable dated October 26, 2020, among Cell MedX Corp. and Rain Communications Corp.
14.1		Code of Ethics⁽³⁾
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101		The following materials from this Quarterly Report on Form 10-Q for the three- and six-month periods ended November 30, 2020 and 2019 formatted in XBRL (extensible Business Reporting Language):
		(1) Unaudited Condensed Consolidated Balance Sheets at November 30, 2020 and as at May 31, 2020.
		(2) Unaudited Condensed Consolidated Statements of Operations for the three- and six-month periods ended November 30, 2020 and 2019.
		(3) Unaudited Condensed Consolidated Statement of Stockholders’ Deficit as at November 30, 2020 and 2019.
		(4) Unaudited Condensed Consolidated Statements of Cash Flows for the six-month periods ended November 30, 2020 and 2019.

(1)Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010

(2)Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010

(3)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014

(4)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014

(5)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014

(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014

(7)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015

(8)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 17, 2017

(9)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2018

(10)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2018

(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2019

(12)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2020

(13)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2020

(14)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 31, 2020

(15)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 15, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Cell MedX Corp.

Date: January 14, 2021	By:	/s/ Frank McEnulty
		Frank McEnulty
		Chief Executive Officer and Director
		(Principal Executive Officer)


Date: January 14, 2021	By:	/s/Yanika Silina
		Yanika Silina
		Chief Financial Officer and Director
		(Principal Accounting Officer)

EX-10.30 2 cmxc_ex1030.htm LOAN AGREEMENT AND NOTE PAYABLE DATED SEPTEMBER 2, 2020, AMONG CELL MEDX CORP. AND RAIN COMMUNICATIONS CORP. ex-10.30

LOAN

AGREEMENT

September 2, 2020

Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$6,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 2, 2020.

The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from September 2, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.

The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.

LENDER	BORROWER
Rain Communications Corp.	Cell MedX Corp.

Per:	Per:


/s/ Raph Biggar	/s/ Yanika Silina
Raph Biggar, President	Yanika Silina, CFO

PROMISSORY NOTE

Principal Amount: USD$6,000

September 2, 2020

FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $6,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from September 2, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.

For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.

The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.

The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.

BORROWER

Cell MedX Corp.

Per:

/s/ Yanika Silina

Yanika Silina, CFO

EX-10.31 3 cmxc_ex1031.htm LOAN AGREEMENT AND NOTE PAYABLE DATED OCTOBER 26, 2020, AMONG CELL MEDX CORP. AND RAIN COMMUNICATIONS CORP. ex-10.31

LOAN

AGREEMENT

October 26, 2020

Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$40,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on October 26, 2020.

The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from October 26, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.

The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.

LENDER	BORROWER
Rain Communications Corp.	Cell MedX Corp.

Per:	Per:


/s/ Raph Biggar	/s/ Yanika Silina
Raph Biggar, President	Yanika Silina, CFO

PROMISSORY NOTE

Principal Amount: USD$40,000

October 26, 2020

FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $40,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from October 26, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.

The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.

The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.

BORROWER

Cell MedX Corp.

Per:

/s/ Yanika Silina

Yanika Silina, CFO

EX-31.1 4 cmxc_ex311.htm CERTIFICATION ex-31.1

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Frank McEnulty, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2020, of Cell MedX Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 14, 2021

/s/ Frank McEnulty

Frank McEnulty

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 5 cmxc_ex312.htm CERTIFICATION ex-31.2

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Yanika Silina, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2020, of Cell MedX Corp.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 14, 2021

/s/ Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)

EX-32.1 6 cmxc_ex321.htm CERTIFICATION ex-32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 14, 2021

/s/ Frank McEnulty

Frank McEnulty

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 7 cmxc_ex322.htm CERTIFICATION ex-32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 14, 2021

/s/Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)

EX-101.INS 8 cmxc-20201130.xml 0001493712 --05-31 Cell MedX Corp. Non-accelerated Filer Yes Yes false true false 10-Q 2020-11-30 000-54500 NV 38-3939625 123 W. Nye Ln, Suite 446 Carson City NV 89706 844 238-2692 59388564 false 2021 Q2 true false

21784

45090

53051

51886

20748

60367

95583

157343

97721

159179

390709

908783

10350

34565

734237

233738

646173

502437

1781469

1679523

0.001

300000000

59388564

55915709

59389

55916

6355923

5988153

80000

366493 366493

-8049520

-25495

38614

97721

159179

1871

10237

3338

30538

988

522

1357

5897

632

545

62447

61728

139387

150999

19173

261

35620

80723

132080

113503

218642

38538

95894

123675

156607

182340

309420

378194

562681

7879

3783

-189336

-303488

-7227

453

-64109

-6488

-196563

-303035

-454647

-555263

-0.00

-0.01

59388564

55075636

58054426

51139321

44282749

44283

5109866

14400

-6956822

15714

-1772559

4050000

4050

481950

486000

7482960

7483

-374148

366665

-548775

-6488

55815709

55816

5958481

14400

-7505597

9226

-1467674

55915709

55916

80000

5988153

366493

-8049520

38614

-1520344

988000

988

-80000

246012

167000

2484855

2485

121758

124243

-390538

-64109

59388564

59389

6355923

366493

-8440058

-25495

-1683748

-390538

-548775

14325

10735

1368

813

-48686

-2909

11000 0

-2070

3293

-29937

-11849

24776

58529

-24545

2823

-244

66520

-8898

-313773

-479370

1574

2463

-1574

-2463

15000

125773

197650

167000

486000

292773

698650

-732

1002

-23306

217819

45090

57172

21784

274991

374148

124243

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS Cell MedX Corp. (Cell MedX, or the Company) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (Cell MedX Canada) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. Unaudited Interim Financial StatementsThe unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the SEC). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2020, included in the Companys Annual Report on Form 10-K, filed with the SEC on September 15, 2020. The interim unaudited condensed consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three- and six-month periods ended November 30, 2020, are not necessarily indicative of the results that may be expected for the year ending May 31, 2021. Going concernThe accompanying unaudited interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2020, the Company has not achieved profitable operations and has accumulated a deficit of $8,440,058. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock. Risks related to the rapid expansion of the COVID-19 pandemicThe Company is cognizant of the rapid expansion of the COVID-19 pandemic and the resulting global implications. To date, the Company has experienced minor disruptions to the Companys day-to-day operations associated with delayed services resulting from various COVID-19 restrictions and shortage of man power experienced by some of the Companys service providers. The Company cautions that there continues to be a possibility for increase of the restrictions currently in place, or addition of new restrictions currently not known to the Company. The impact of these restrictions on the Companys operations, if implemented, is currently unknown but could be significant.

-8440058

NOTE 2 - RELATED PARTY TRANSACTIONS Amounts due to related parties, other than advances and notes payable to related parties (Note 7) at November 30, 2020, and at May 31, 2020: <table style='border-collapse:collapse;width:96.26%'><tr align="left"><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:16.08%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2020</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>May 31, 2020</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>Due to the Chief Executive Officer (CEO)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%;border-top:0.5pt solid #000000'>109,200</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>103,200</td></tr><tr align="left"><td valign="top">Due to the Chief Financial Officer (CFO)</td><td valign="bottom" style='width:3.42%'> </td><td valign="top" style='width:12.66%'>7,966</td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">9,533</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Due to the Vice President (VP), Technology and Operations</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%'>-</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1">34,219</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Due (from) the Vice President (VP), Technology and Operations</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%'>3,424</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1">-</td></tr><tr align="left"><td valign="top">Due to a company controlled by the Chief Operating Officer (COO)(1)</td><td valign="bottom" style='width:3.42%'> </td><td valign="top" style='width:12.66%'>618,122</td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Due to a major shareholder</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%'>-</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1">86,786</td></tr><tr align="left"><td valign="top">Due to a company controlled by the COO and major shareholder</td><td valign="bottom" style='width:3.42%'> </td><td valign="bottom" style='width:12.66%'>2,250</td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'>Due to a company of which the COO is a director of</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:12.66%;border-bottom:0.5pt solid #000000'>123</td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'>n/a</td></tr><tr align="left"><td valign="top" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Due to related parties</td><td valign="bottom" style='width:3.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:12.66%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>734,237</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>233,738</td></tr></table><kbd style='position:absolute;font:8pt Arial;margin-left:-36pt'>(1)</kbd>John da Costa was appointed Director and Chief Operating Officer of the Company on June 8, 2020, as of that date any company controlled by Mr. Da Costa is considered to be a related entity.  The amounts due to related parties are unsecured, due on demand and bear no interest. During the six-month periods ended November 30, 2020 and 2019, the Company had the following transactions with related parties: <table style='border-collapse:collapse;width:99%'><tr align="left"><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:18.8%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2020</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:20.4%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2019</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>Management fees incurred to the CEO</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:13.98%;border-top:0.5pt solid #000000'>6,000</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.34%;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:16.06%;border-top:0.5pt solid #000000'>21,600</td></tr><tr align="left"><td valign="top">Management fees incurred to the CFO</td><td valign="bottom"> </td><td valign="bottom" style='width:13.98%'>13,500</td><td valign="bottom"> </td><td valign="bottom" style='width:4.34%'> </td><td valign="bottom" style='width:16.06%'>6,000</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Consulting fees incurred to the VP, Technology and Operations</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:13.98%'>22,337</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.34%'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:16.06%'>22,593</td></tr><tr align="left"><td valign="top">Consulting fees incurred to the company controlled by the COO</td><td valign="bottom"> </td><td valign="bottom" style='width:13.98%'>77,378</td><td valign="bottom"> </td><td valign="bottom" style='width:4.34%'> </td><td valign="bottom" style='width:16.06%'>n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'>Royalty incurred to the company of which the COO is a director of </td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:13.98%;border-bottom:0.5pt solid #000000'>53</td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.34%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:16.06%;border-bottom:0.5pt solid #000000'>n/a</td></tr><tr align="left"><td valign="top" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Total transactions with related parties</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:13.98%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>119,268</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:4.34%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:16.06%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>50,193</td></tr></table>

<table style='border-collapse:collapse;width:96.26%'><tr align="left"><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:16.08%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2020</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>May 31, 2020</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>Due to the Chief Executive Officer (CEO)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%;border-top:0.5pt solid #000000'>109,200</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>103,200</td></tr><tr align="left"><td valign="top">Due to the Chief Financial Officer (CFO)</td><td valign="bottom" style='width:3.42%'> </td><td valign="top" style='width:12.66%'>7,966</td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">9,533</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Due to the Vice President (VP), Technology and Operations</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%'>-</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1">34,219</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Due (from) the Vice President (VP), Technology and Operations</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%'>3,424</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1">-</td></tr><tr align="left"><td valign="top">Due to a company controlled by the Chief Operating Officer (COO)(1)</td><td valign="bottom" style='width:3.42%'> </td><td valign="top" style='width:12.66%'>618,122</td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Due to a major shareholder</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:12.66%'>-</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1">86,786</td></tr><tr align="left"><td valign="top">Due to a company controlled by the COO and major shareholder</td><td valign="bottom" style='width:3.42%'> </td><td valign="bottom" style='width:12.66%'>2,250</td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'>Due to a company of which the COO is a director of</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.42%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:12.66%;border-bottom:0.5pt solid #000000'>123</td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'>n/a</td></tr><tr align="left"><td valign="top" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Due to related parties</td><td valign="bottom" style='width:3.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:12.66%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>734,237</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>233,738</td></tr></table>

109200

103200

7966

9533

34219

3424

618122

86786

2250

123

734237

233738

<table style='border-collapse:collapse;width:99%'><tr align="left"><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:18.8%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2020</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:20.4%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2019</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>Management fees incurred to the CEO</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:13.98%;border-top:0.5pt solid #000000'>6,000</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.34%;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:16.06%;border-top:0.5pt solid #000000'>21,600</td></tr><tr align="left"><td valign="top">Management fees incurred to the CFO</td><td valign="bottom"> </td><td valign="bottom" style='width:13.98%'>13,500</td><td valign="bottom"> </td><td valign="bottom" style='width:4.34%'> </td><td valign="bottom" style='width:16.06%'>6,000</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Consulting fees incurred to the VP, Technology and Operations</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:13.98%'>22,337</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.34%'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:16.06%'>22,593</td></tr><tr align="left"><td valign="top">Consulting fees incurred to the company controlled by the COO</td><td valign="bottom"> </td><td valign="bottom" style='width:13.98%'>77,378</td><td valign="bottom"> </td><td valign="bottom" style='width:4.34%'> </td><td valign="bottom" style='width:16.06%'>n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'>Royalty incurred to the company of which the COO is a director of </td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:13.98%;border-bottom:0.5pt solid #000000'>53</td><td valign="bottom" bgcolor="#DBE5F1" style='border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.34%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:16.06%;border-bottom:0.5pt solid #000000'>n/a</td></tr><tr align="left"><td valign="top" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Total transactions with related parties</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:13.98%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>119,268</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:4.34%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:16.06%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>50,193</td></tr></table>

6000

21600

13500

6000

22337

22593

77378

119268

50193

NOTE 3 - INVENTORY As at November 30, 2020, the inventory consisted of eBalance® devices and accessories held for sale valued at $29,290 (May 31, 2020 - $29,405) and work in progress, that included unfinished eBalance® devices and supplies required for manufacturing valued at $23,761 (May 31, 2020 - $22,481).

29290

29405

23761

22481

NOTE 4 - OTHER CURRENT ASSETS As at November 30, 2020, other current assets consisted of $14,325 in prepaid expenses (May 31, 2020 - $44,021) and $6,423 in receivables associated with GST Cell MedX Canada paid on taxable supplies (May 31, 2020 - $16,346).

14325

44021

6423

16346

NOTE 5 - EQUIPMENT Changes in the net book value of the equipment at November 30, 2020 and May 31, 2020 are as follows: <table style='border-collapse:collapse;width:80%'><tr align="left"><td valign="top" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2020</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>May 31, 2020</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>Book value, beginning of the period</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>1,836</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>1,281</td></tr><tr align="left"><td valign="top">Changes during the period</td><td valign="bottom"> </td><td valign="top">1,574</td><td valign="top"> </td><td valign="top"> </td><td valign="top">2,463</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Amortization</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="top" bgcolor="#DBE5F1">1,368</td><td valign="top" bgcolor="#DBE5F1"> </td><td valign="top" bgcolor="#DBE5F1"> </td><td valign="top" bgcolor="#DBE5F1">1,846</td></tr><tr align="left"><td valign="top" style='border-bottom:0.5pt solid #000000'>Foreign exchange</td><td valign="bottom" style='border-bottom:0.5pt solid #000000'> </td><td valign="top" style='border-bottom:0.5pt solid #000000'>96</td><td valign="top" style='border-bottom:0.5pt solid #000000'> </td><td valign="top" style='border-bottom:0.5pt solid #000000'> </td><td valign="top" style='border-bottom:0.5pt solid #000000'>(62)</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Book value, end of the period</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>2,138</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>1,836</td></tr></table>

<table style='border-collapse:collapse;width:80%'><tr align="left"><td valign="top" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>November 30, 2020</td><td valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>May 31, 2020</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>Book value, beginning of the period</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>1,836</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000'>1,281</td></tr><tr align="left"><td valign="top">Changes during the period</td><td valign="bottom"> </td><td valign="top">1,574</td><td valign="top"> </td><td valign="top"> </td><td valign="top">2,463</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1">Amortization</td><td valign="bottom" bgcolor="#DBE5F1"> </td><td valign="top" bgcolor="#DBE5F1">1,368</td><td valign="top" bgcolor="#DBE5F1"> </td><td valign="top" bgcolor="#DBE5F1"> </td><td valign="top" bgcolor="#DBE5F1">1,846</td></tr><tr align="left"><td valign="top" style='border-bottom:0.5pt solid #000000'>Foreign exchange</td><td valign="bottom" style='border-bottom:0.5pt solid #000000'> </td><td valign="top" style='border-bottom:0.5pt solid #000000'>96</td><td valign="top" style='border-bottom:0.5pt solid #000000'> </td><td valign="top" style='border-bottom:0.5pt solid #000000'> </td><td valign="top" style='border-bottom:0.5pt solid #000000'>(62)</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Book value, end of the period</td><td valign="bottom" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>2,138</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'>1,836</td></tr></table>

1574

2463

1368

1846

96 -62

2138

1836

NOTE 6 - REVENUE During the six-month period ended November 30, 2020, the Companys revenue consisted of monthly subscriptions to eBalance® microcurrent treatments. During the comparative six-month period ended November 30, 2019, the Companys revenue consisted of sales of its eBalance® devices, and the fees associated with the rights to the wholesale distribution of eBalance® devices pursuant to a letter of intent the Company entered into on June 6, 2019, which granted a potential distributor rights to all Mainland China, not including Hong Kong.  Following are the details of revenue and associated costs: <table style='border-collapse:collapse;width:90%'><tr align="left"><td valign="top" style='width:43.06%;border-top:0.5pt solid #000000'> </td><td colspan="4" valign="bottom" style='width:26.48%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Three months endedNovember 30,</td><td colspan="4" valign="bottom" style='width:30.46%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Six months endedNovember 30,</td></tr><tr align="left"><td valign="top" style='width:43.06%;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:12.92%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2020</td><td colspan="2" valign="bottom" style='width:13.56%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2019</td><td colspan="2" valign="bottom" style='width:15.26%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2020</td><td colspan="2" valign="bottom" style='width:15.22%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2019</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:43.06%;border-top:0.5pt solid #000000'>Sales of eBalance® devices</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.4%;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:9.52%;border-top:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.02%;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:9.54%;border-top:0.5pt solid #000000'>757</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.06%;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:11.18%;border-top:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.04%;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:11.18%;border-top:0.5pt solid #000000'>12,100</td></tr><tr align="left"><td valign="top" style='width:43.06%'>Monthly subscriptions</td><td valign="bottom" style='width:3.4%'> </td><td valign="top" style='width:9.52%'>1,871</td><td valign="bottom" style='width:4.02%'> </td><td valign="bottom" style='width:9.54%'>-</td><td valign="top" style='width:4.06%'> </td><td valign="top" style='width:11.18%'>3,338</td><td valign="bottom" style='width:4.04%'> </td><td valign="bottom" style='width:11.18%'>-</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:43.06%'>Cost of eBalance® devices and services</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.4%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:9.52%'>(958)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.02%'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:9.54%'>(434)</td><td valign="top" bgcolor="#DBE5F1" style='width:4.06%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:11.18%'>(1,304)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.04%'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:11.18%'>(4,485)</td></tr><tr align="left"><td valign="top" style='width:43.06%'>Royalty payable</td><td valign="bottom" style='width:3.4%'> </td><td valign="top" style='width:9.52%'>(30)</td><td valign="bottom" style='width:4.02%'> </td><td valign="bottom" style='width:9.54%'>(88)</td><td valign="top" style='width:4.06%'> </td><td valign="top" style='width:11.18%'>(53)</td><td valign="bottom" style='width:4.04%'> </td><td valign="bottom" style='width:11.18%'>(1,412)</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:43.06%;border-bottom:0.5pt solid #000000'>Distribution rights</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.4%;border-bottom:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:9.52%;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.02%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:9.54%;border-bottom:0.5pt solid #000000'>9,480</td><td valign="top" bgcolor="#DBE5F1" style='width:4.06%;border-bottom:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:11.18%;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.04%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:11.18%;border-bottom:0.5pt solid #000000'>18,438</td></tr><tr align="left"><td valign="top" style='width:43.06%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Gross margin</td><td valign="bottom" style='width:3.4%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" style='width:9.52%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>883</td><td valign="bottom" style='width:4.02%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:9.54%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>9,715</td><td valign="bottom" style='width:4.06%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" style='width:11.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>1,981</td><td valign="bottom" style='width:4.04%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:11.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>24,641</td></tr></table>

<table style='border-collapse:collapse;width:90%'><tr align="left"><td valign="top" style='width:43.06%;border-top:0.5pt solid #000000'> </td><td colspan="4" valign="bottom" style='width:26.48%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Three months endedNovember 30,</td><td colspan="4" valign="bottom" style='width:30.46%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Six months endedNovember 30,</td></tr><tr align="left"><td valign="top" style='width:43.06%;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:12.92%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2020</td><td colspan="2" valign="bottom" style='width:13.56%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2019</td><td colspan="2" valign="bottom" style='width:15.26%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2020</td><td colspan="2" valign="bottom" style='width:15.22%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>2019</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:43.06%;border-top:0.5pt solid #000000'>Sales of eBalance® devices</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.4%;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:9.52%;border-top:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.02%;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:9.54%;border-top:0.5pt solid #000000'>757</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.06%;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:11.18%;border-top:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.04%;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:11.18%;border-top:0.5pt solid #000000'>12,100</td></tr><tr align="left"><td valign="top" style='width:43.06%'>Monthly subscriptions</td><td valign="bottom" style='width:3.4%'> </td><td valign="top" style='width:9.52%'>1,871</td><td valign="bottom" style='width:4.02%'> </td><td valign="bottom" style='width:9.54%'>-</td><td valign="top" style='width:4.06%'> </td><td valign="top" style='width:11.18%'>3,338</td><td valign="bottom" style='width:4.04%'> </td><td valign="bottom" style='width:11.18%'>-</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:43.06%'>Cost of eBalance® devices and services</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.4%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:9.52%'>(958)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.02%'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:9.54%'>(434)</td><td valign="top" bgcolor="#DBE5F1" style='width:4.06%'> </td><td valign="top" bgcolor="#DBE5F1" style='width:11.18%'>(1,304)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.04%'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:11.18%'>(4,485)</td></tr><tr align="left"><td valign="top" style='width:43.06%'>Royalty payable</td><td valign="bottom" style='width:3.4%'> </td><td valign="top" style='width:9.52%'>(30)</td><td valign="bottom" style='width:4.02%'> </td><td valign="bottom" style='width:9.54%'>(88)</td><td valign="top" style='width:4.06%'> </td><td valign="top" style='width:11.18%'>(53)</td><td valign="bottom" style='width:4.04%'> </td><td valign="bottom" style='width:11.18%'>(1,412)</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:43.06%;border-bottom:0.5pt solid #000000'>Distribution rights</td><td valign="bottom" bgcolor="#DBE5F1" style='width:3.4%;border-bottom:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:9.52%;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.02%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:9.54%;border-bottom:0.5pt solid #000000'>9,480</td><td valign="top" bgcolor="#DBE5F1" style='width:4.06%;border-bottom:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:11.18%;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:4.04%;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:11.18%;border-bottom:0.5pt solid #000000'>18,438</td></tr><tr align="left"><td valign="top" style='width:43.06%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Gross margin</td><td valign="bottom" style='width:3.4%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" style='width:9.52%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>883</td><td valign="bottom" style='width:4.02%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:9.54%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>9,715</td><td valign="bottom" style='width:4.06%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" style='width:11.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>1,981</td><td valign="bottom" style='width:4.04%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:11.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>24,641</td></tr></table>

757

12100

1871

3338

958

434

1304

4485

1412

9480

18438

883

9715

1981

24641

NOTE 7 - NOTES AND ADVANCES PAYABLE The tables below summarize the short-term loans and advances outstanding as at November 30, 2020, and May 31, 2020: <table style='border-collapse:collapse;width:90%'><tr align="left"><td colspan="8" valign="bottom" style='width:430.9pt;border-bottom:0.5pt solid #000000'>As at November 30, 2020</td></tr><tr align="left"><td colspan="2" valign="bottom" style='width:83.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>PrincipalOutstanding</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Interest Rateper Annum</td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:69.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>AccruedInterest(6)</td><td colspan="2" valign="bottom" style='width:81.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Total BookValue</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt;border-top:0.5pt solid #000000'>327,650</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-top:0.5pt solid #000000'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-top:0.5pt solid #000000'>Convertible(1)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-top:0.5pt solid #000000'>21,039</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-top:0.5pt solid #000000'>348,689</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="top" style='width:57.3pt'>141,065</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Non-convertible(2)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>5,942</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>147,007</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt'>7,045</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt'>Related party(3)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt'>552</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt'>7,597</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="top" style='width:57.3pt'>35,606</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Related party(4)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>2,789</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>38,395</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt'>15,426</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt'>Related party(3)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt'>369</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt'>15,795</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="top" style='width:57.3pt'>40,440</td><td valign="bottom" style='width:77.5pt'>0%</td><td valign="bottom" style='width:119pt'>Related party advances(5)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>-</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>40,440</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt;border-bottom:0.5pt solid #000000'>48,250</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-bottom:0.5pt solid #000000'>0%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-bottom:0.5pt solid #000000'>Advances(5)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-bottom:0.5pt solid #000000'>48,250</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" style='width:57.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>615,482</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>30,691</td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>646,173</td></tr><tr align="left"><td colspan="8" valign="bottom" style='width:430.9pt;border-top:3px double #000000'> </td></tr><tr align="left"><td colspan="8" valign="bottom" style='width:430.9pt;border-bottom:0.5pt solid #000000'>As at May 31, 2020</td></tr><tr align="left"><td colspan="2" valign="bottom" style='width:83.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>PrincipalOutstanding</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Interest Rateper Annum</td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:69.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>AccruedInterest(6)</td><td colspan="2" valign="bottom" style='width:81.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Total BookValue</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:57.3pt;border-top:0.5pt solid #000000'>327,650</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-top:0.5pt solid #000000'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-top:0.5pt solid #000000'>Convertible(1)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-top:0.5pt solid #000000'>10,731</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-top:0.5pt solid #000000'>338,381</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:57.3pt'>28,630</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Non-convertible(2)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>3,464</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>32,094</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:57.3pt'>6,625</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt'>Related party(3)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt'>308</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt'>6,933</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:57.3pt'>35,606</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Related party(4)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>1,654</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>37,260</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:57.3pt;border-bottom:0.5pt solid #000000'>87,769</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-bottom:0.5pt solid #000000'>0%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-bottom:0.5pt solid #000000'>Advances(5)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-bottom:0.5pt solid #000000'>87,769</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:57.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>486,280</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>16,157</td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>502,437</td></tr></table> (1) Convertible Loans PayableDuring the year ended May 31, 2020, in order to support its daily operations and to secure required working capital, the Company entered into several short-term convertible loan agreements with two lenders for a total of $327,650 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly.  Pursuant to the loan agreements, the lenders may convert any portion of principal and/or interest accrued thereon into restricted units of common stock in the capital of the Company on the terms and at a conversion price of the then-current private placement offering. The conversion rights were assessed to have $Nil value. During the six-month period ended November 30, 2020, the Company recorded $10,308 in interest on the convertible loans payable (2020 - $2,668). (2) Non-convertible Loans PayableDuring the six-month period ended November 30, 2020, the Company entered into several short-term loan agreements with two lenders for a total of $111,000 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly. As at November 30, 2020, the Company owed a total of $147,007 (2020 - $32,094) under 6% unsecured loan agreements.  During the six-month period ended November 30, 2020, the Company recorded $2,303 in interest on these loans (2020 - $951). (3) Related Party Loans PayableAs at November 30, 2020, the Company owed a total of $7,597 (2020 - $6,933) under unsecured loan agreement with Mr. Jeffs, the Companys major shareholder. During the six-month period ended November 30, 2020, the Company recorded $219 in interest on the loan with Mr. Jeffs. (2020 - $2,425). On July 9, 2020, the Company entered into a loan agreement for $14,773 (CAD$20,000) with a related party. The loan bears interest at 6% per annum compounded monthly, is unsecured, and payable from the first proceeds of warrants that may be exercised subsequent to the money being lent under the loan agreement or on July 9, 2021, whichever comes first. During the six-month period ended November 30, 2020, the Company recorded $360 in interest on the principal (2020 - $Nil). (4) Unsecured Line of Credit with Related PartyOn December 27, 2018, the Company entered into an agreement with Mr. Jeffs for an unsecured line of credit of up to $250,000 (the Credit Line). The funds advanced under the Credit Line accumulate interest at a rate of 6% per annum compounded monthly and are payable on demand.  On August 28, 2019, Mr. Jeffs applied $250,000, the Company owed under the Credit Line to exercise the warrants the Company granted to Mr. Jeffs in consideration for the Credit Line and acquired 5,000,000 shares of the Companys common stock at $0.05 per share. As at November 30, 2020, the Company owed Mr. Jeffs $38,395 under the Credit Line (2020 - $37,260), which continues to accumulate interest at 6% per annum compounded monthly. During the six-month period ended November 30, 2020, the Company recorded $1,135 in interest on principal outstanding under the Credit Line (2020 - $4,691). (5) Advances PayableAs at November 30, 2020, the Company owed a total of $88,690 (2020 - $87,769) for advances the Company received in its fiscal 2019 and 2020 years. The advances are non-interest bearing, unsecured, and payable on demand. Of the total amount advanced, $3,870 was owed to Da Costa Management Corp, a company owned by John da Costa, who was appointed the Companys COO and Director on June 8, 2020 (2020 - $3,639), $11,570 (2020 - $10,880) was owed to Brek Technologies Inc., a company controlled by Mr. da Costa and Mr. Jeffs (Note 2), and $25,000 (2020 - $25,000) was owed to Mr. David Jeffs, the CEO and President of Live Current Media, Inc., of which Mr. da Costa is director of. (6) Interest ExpenseDuring the six-month period ended November 30, 2020, the Company recorded a total of $14,325 (2020 - $10,735) in interest expense associated with its liabilities under the notes and advances payable.

<table style='border-collapse:collapse;width:90%'><tr align="left"><td colspan="8" valign="bottom" style='width:430.9pt;border-bottom:0.5pt solid #000000'>As at November 30, 2020</td></tr><tr align="left"><td colspan="2" valign="bottom" style='width:83.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>PrincipalOutstanding</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Interest Rateper Annum</td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:69.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>AccruedInterest(6)</td><td colspan="2" valign="bottom" style='width:81.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Total BookValue</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt;border-top:0.5pt solid #000000'>327,650</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-top:0.5pt solid #000000'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-top:0.5pt solid #000000'>Convertible(1)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-top:0.5pt solid #000000'>21,039</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-top:0.5pt solid #000000'>348,689</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="top" style='width:57.3pt'>141,065</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Non-convertible(2)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>5,942</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>147,007</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt'>7,045</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt'>Related party(3)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt'>552</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt'>7,597</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="top" style='width:57.3pt'>35,606</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Related party(4)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>2,789</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>38,395</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt'>15,426</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt'>Related party(3)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt'>369</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt'>15,795</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="top" style='width:57.3pt'>40,440</td><td valign="bottom" style='width:77.5pt'>0%</td><td valign="bottom" style='width:119pt'>Related party advances(5)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>-</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>40,440</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:57.3pt;border-bottom:0.5pt solid #000000'>48,250</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-bottom:0.5pt solid #000000'>0%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-bottom:0.5pt solid #000000'>Advances(5)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-bottom:0.5pt solid #000000'>48,250</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="top" style='width:57.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>615,482</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>30,691</td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>646,173</td></tr><tr align="left"><td colspan="8" valign="bottom" style='width:430.9pt;border-top:3px double #000000'> </td></tr><tr align="left"><td colspan="8" valign="bottom" style='width:430.9pt;border-bottom:0.5pt solid #000000'>As at May 31, 2020</td></tr><tr align="left"><td colspan="2" valign="bottom" style='width:83.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>PrincipalOutstanding</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Interest Rateper Annum</td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'> </td><td colspan="2" valign="bottom" style='width:69.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>AccruedInterest(6)</td><td colspan="2" valign="bottom" style='width:81.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Total BookValue</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:57.3pt;border-top:0.5pt solid #000000'>327,650</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-top:0.5pt solid #000000'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-top:0.5pt solid #000000'>Convertible(1)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-top:0.5pt solid #000000'>10,731</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-top:0.5pt solid #000000'>338,381</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:57.3pt'>28,630</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Non-convertible(2)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>3,464</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>32,094</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:57.3pt'>6,625</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt'>6%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt'>Related party(3)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt'>308</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt'>6,933</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:57.3pt'>35,606</td><td valign="bottom" style='width:77.5pt'>6%</td><td valign="bottom" style='width:119pt'>Related party(4)</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:43.8pt'>1,654</td><td valign="bottom" style='width:26.1pt'> </td><td valign="bottom" style='width:55pt'>37,260</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:57.3pt;border-bottom:0.5pt solid #000000'>87,769</td><td valign="bottom" bgcolor="#DBE5F1" style='width:77.5pt;border-bottom:0.5pt solid #000000'>0%</td><td valign="bottom" bgcolor="#DBE5F1" style='width:119pt;border-bottom:0.5pt solid #000000'>Advances(5)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.8pt;border-bottom:0.5pt solid #000000'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:26.1pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:55pt;border-bottom:0.5pt solid #000000'>87,769</td></tr><tr align="left"><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:57.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>486,280</td><td valign="bottom" style='width:77.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:119pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>16,157</td><td valign="bottom" style='width:26.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>502,437</td></tr></table>

327650

0.0600

21039

348689

141065

0.0600

5942

147007

7045

0.0600

552

7597

35606

0.0600

2789

38395

15426

0.0600

369

15795

40440

0.0000

40440

48250

0.0000

48250

615482

30691

646173

327650

0.0600

10731

338381

28630

0.0600

3464

32094

6625

0.0600

308

6933

35606

0.0600

1654

37260

87769

0.0000

87769

486280

16157

502437

10308

2668

147007

32094

2303

951

7597

6933

219

2425

14773

360

38395

37260

1135

4691

88690

87769

14325

10735

NOTE 8 - SHARE CAPITAL On July 30, 2020, the Company issued 988,000 units of its common stock for gross proceeds of $247,000, of which $80,000 were received during the year ended May 31, 2020. Each unit consisted of one common share of the Company and one warrant allowing its holder to acquire an additional common share at $0.35 until January 30, 2021, and at $0.50 per share from January 30, 2021 to July 30, 2022. On August 13, 2020, the Company issued 1,250,000 shares of its common stock to Ms. Arnett, the Companys 10% shareholder, on the exercise of 1,250,000 options at $0.05 per option. Ms. Arnett chose to apply $62,500 the Company owed to her on account of past services against the exercise price of the shares. Ms. Arnett transferred the remaining $24,712 the Company owed to her as at August 13, 2020, to Mr. Hargreaves, the Companys director of VP; Technology and Operations, in a private transaction. On August 13, 2020, the Company issued 1,234,855 shares of its common stock to Mr. Hargreaves, the Companys VP; Technology and Operations, on the exercise of 1,234,855 shares at $0.05 per option. Mr. Hargreaves chose to apply $61,743 the Company owed to him against the exercise price of the shares. Options The changes in the number of stock options outstanding during the six-month period ended November 30, 2020, and for the year ended May 31, 2020, are as follows: <table style='border-collapse:collapse;width:99%'><tr align="left"><td valign="top" style='width:167.6pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:148.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Six months endedNovember 30, 2020</td><td valign="bottom" style='width:15.1pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:142.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Year endedMay 31, 2020</td></tr><tr align="left"><td valign="top" style='width:167.6pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" style='width:71.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofoptions</td><td colspan="2" valign="bottom" style='width:76.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td><td valign="bottom" style='width:15.1pt'> </td><td valign="bottom" style='width:64.7pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofoptions</td><td colspan="2" valign="bottom" style='width:78.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:167.6pt;border-top:0.5pt solid #000000'>Options outstanding, beginning</td><td valign="bottom" bgcolor="#DBE5F1" style='width:71.75pt;border-top:0.5pt solid #000000'>7,050,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:33.2pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt;border-top:0.5pt solid #000000'>0.24</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:64.7pt;border-top:0.5pt solid #000000'>7,050,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:34.55pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt;border-top:0.5pt solid #000000'>0.24</td></tr><tr align="left"><td valign="top" style='width:167.6pt'>Options exercised</td><td valign="bottom" style='width:71.75pt'>(2,484,855)</td><td valign="bottom" style='width:33.2pt'>$</td><td valign="bottom" style='width:43.55pt'>0.05</td><td valign="bottom" style='width:15.1pt'> </td><td valign="bottom" style='width:64.7pt'>-</td><td valign="bottom" style='width:34.55pt'>$</td><td valign="bottom" style='width:43.55pt'>n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:167.6pt'>Options expired</td><td valign="top" bgcolor="#DBE5F1" style='width:71.75pt'>(1,015,145)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:33.2pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt'>0.34</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:64.7pt'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:34.55pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt'>n/a</td></tr><tr align="left"><td valign="top" style='width:167.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Options outstanding, ending</td><td valign="top" style='width:71.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>3,550,000</td><td valign="bottom" style='width:33.2pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.35</td><td valign="bottom" style='width:15.1pt'> </td><td valign="bottom" style='width:64.7pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>7,050,000</td><td valign="bottom" style='width:34.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.24</td></tr></table> Details of options outstanding and exercisable as at November 30, 2020, are as follows: <table style='border-collapse:collapse;width:98.88%'><tr align="left"><td valign="bottom" style='width:35.36%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number of options outstandingand exercisable</td><td valign="bottom" style='width:14.26%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Exerciseprice</td><td valign="bottom" style='width:24.7%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Grant date</td><td valign="bottom" style='width:25.68%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Expiry date</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:35.36%;border-top:0.5pt solid #000000'>500,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:14.26%;border-top:0.5pt solid #000000'>$0.35</td><td valign="bottom" bgcolor="#DBE5F1" style='width:24.7%;border-top:0.5pt solid #000000'>August 5, 2015</td><td valign="bottom" bgcolor="#DBE5F1" style='width:25.68%;border-top:0.5pt solid #000000'>January 1, 2021</td></tr><tr align="left"><td valign="bottom" style='width:35.36%'>500,000</td><td valign="bottom" style='width:14.26%'>$0.35</td><td valign="bottom" style='width:24.7%'>August 5, 2015</td><td valign="bottom" style='width:25.68%'>April 1, 2021</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:35.36%'>500,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:14.26%'>$0.35</td><td valign="bottom" bgcolor="#DBE5F1" style='width:24.7%'>August 5, 2015</td><td valign="bottom" bgcolor="#DBE5F1" style='width:25.68%'>July 1, 2021</td></tr><tr align="left"><td valign="bottom" style='width:35.36%;border-bottom:0.5pt solid #000000'>2,050,000</td><td valign="bottom" style='width:14.26%;border-bottom:0.5pt solid #000000'>$0.35</td><td valign="bottom" style='width:24.7%;border-bottom:0.5pt solid #000000'>August 24, 2017</td><td valign="bottom" style='width:25.68%;border-bottom:0.5pt solid #000000'>August 23, 2022</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:35.36%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>3,550,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:14.26%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$0.35</td><td valign="bottom" bgcolor="#DBE5F1" style='width:24.7%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:25.68%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td></tr></table> At November 30, 2020, the weighted average remaining contractual life of the stock options outstanding was 1.14 years. Warrants The changes in the number of warrants outstanding during the six-month period ended November 30, 2020, and for the year ended May 31, 2020, are as follows: <table style='border-collapse:collapse;width:95%'><tr align="left"><td valign="top" style='width:146.6pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:145.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Six months endedNovember 30, 2020</td><td valign="bottom" style='width:15pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:136.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Year endedMay 31, 2020</td></tr><tr align="left"><td valign="top" style='width:146.6pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" style='width:69.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofwarrants</td><td colspan="2" valign="bottom" style='width:75.55pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td><td valign="bottom" style='width:15pt'> </td><td valign="bottom" style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofwarrants</td><td colspan="2" valign="bottom" style='width:73.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:146.6pt;border-top:0.5pt solid #000000'>Warrants outstanding, beginning</td><td valign="middle" bgcolor="#DBE5F1" style='width:69.85pt;border-top:0.5pt solid #000000'>18,864,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:54.75pt;border-top:0.5pt solid #000000'>0.94</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15pt'> </td><td valign="middle" bgcolor="#DBE5F1" style='width:63pt;border-top:0.5pt solid #000000'>20,297,565</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:53.05pt;border-top:0.5pt solid #000000'>0.78</td></tr><tr align="left"><td valign="top" style='width:146.6pt;border-top:0.5pt solid #000000'>Warrants issued</td><td valign="bottom" style='width:69.85pt;border-top:0.5pt solid #000000'>988,000</td><td valign="bottom" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" style='width:54.75pt;border-top:0.5pt solid #000000'>0.35/$0.50</td><td valign="bottom" style='width:15pt'> </td><td valign="middle" style='width:63pt;border-top:0.5pt solid #000000'>6,050,000</td><td valign="bottom" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" style='width:53.05pt;border-top:0.5pt solid #000000'>0.38</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:146.6pt'>Warrants exercised</td><td valign="bottom" bgcolor="#DBE5F1" style='width:69.85pt'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:54.75pt'>n/a</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15pt'> </td><td valign="middle" bgcolor="#DBE5F1" style='width:63pt'>7,482,960</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:53.05pt'>0.05</td></tr><tr align="left"><td valign="top" style='width:146.6pt'>Warrants expired</td><td valign="middle" style='width:69.85pt'>1,480,000</td><td valign="bottom" style='width:20.8pt'>$</td><td valign="bottom" style='width:54.75pt'>1.50</td><td valign="bottom" style='width:15pt'> </td><td valign="middle" style='width:63pt'>-</td><td valign="bottom" style='width:20.8pt'>$</td><td valign="bottom" style='width:53.05pt'>n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:146.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Warrants outstanding, ending</td><td valign="middle" bgcolor="#DBE5F1" style='width:69.85pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>18,372,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:54.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.86</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15pt'> </td><td valign="middle" bgcolor="#DBE5F1" style='width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>18,864,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:53.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.94</td></tr></table> Details of warrants outstanding as at November 30, 2020, are as follows: <table style='border-collapse:collapse;width:100%;margin-left:0.9pt'><tr align="left"><td valign="bottom" style='width:21.74%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number of warrantsexercisable</td><td valign="bottom" style='width:17.78%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Grant date</td><td valign="bottom" style='width:60.48%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Exercise price</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:21.74%;border-top:0.5pt solid #000000'>2,000,000</td><td valign="top" bgcolor="#DBE5F1" style='width:17.78%;border-top:0.5pt solid #000000'>March 3, 2016</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%;border-top:0.5pt solid #000000'>$0.75 expiring on March 3, 2021</td></tr><tr align="left"><td valign="top" style='width:21.74%'>9,094,605</td><td valign="top" style='width:17.78%'>October 12, 2016</td><td valign="top" style='width:60.48%'>$1.50 expiring on October 12, 2021</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%'>240,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%'>February 7, 2018</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%'>$1.50 expiring on February 7, 2021</td></tr><tr align="left"><td valign="bottom" style='width:21.74%'>3,950,000</td><td valign="bottom" style='width:17.78%'>June 24, 2019</td><td valign="top" style='width:60.48%'>$0.20 expiring on June 24, 2021</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%'>100,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%'>July 22, 2019</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%'>$0.20 expiring on July 22, 2021</td></tr><tr align="left"><td valign="bottom" style='width:21.74%'>1,000,000</td><td valign="bottom" style='width:17.78%'>January 29, 2020</td><td valign="top" style='width:60.48%'>$0.50 expiring on March 12, 2023</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%'>1,000,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%'>January 29, 2020</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%'>$1.00 expiring on March 12, 2023</td></tr><tr align="left"><td valign="top" style='width:21.74%;border-bottom:0.5pt solid #000000'>988,000</td><td valign="top" style='width:17.78%;border-bottom:0.5pt solid #000000'>July 30, 2020</td><td valign="top" style='width:60.48%;border-bottom:0.5pt solid #000000'>$0.35 during the period from July 30, 2020 to January 30, 2021$0.50 during the period from January 30, 2021 to July 30, 2022</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>18,372,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td></tr></table> At November 30, 2020, the weighted average life of the warrants was 0.86 years.

988000

80000

Each unit consisted of one common share of the Company and one warrant allowing its holder to acquire an additional common share at $0.35 until January 30, 2021, and at $0.50 per share from January 30, 2021 to July 30, 2022

1250000

1234855

<table style='border-collapse:collapse;width:99%'><tr align="left"><td valign="top" style='width:167.6pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:148.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Six months endedNovember 30, 2020</td><td valign="bottom" style='width:15.1pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:142.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Year endedMay 31, 2020</td></tr><tr align="left"><td valign="top" style='width:167.6pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" style='width:71.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofoptions</td><td colspan="2" valign="bottom" style='width:76.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td><td valign="bottom" style='width:15.1pt'> </td><td valign="bottom" style='width:64.7pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofoptions</td><td colspan="2" valign="bottom" style='width:78.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:167.6pt;border-top:0.5pt solid #000000'>Options outstanding, beginning</td><td valign="bottom" bgcolor="#DBE5F1" style='width:71.75pt;border-top:0.5pt solid #000000'>7,050,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:33.2pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt;border-top:0.5pt solid #000000'>0.24</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:64.7pt;border-top:0.5pt solid #000000'>7,050,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:34.55pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt;border-top:0.5pt solid #000000'>0.24</td></tr><tr align="left"><td valign="top" style='width:167.6pt'>Options exercised</td><td valign="bottom" style='width:71.75pt'>(2,484,855)</td><td valign="bottom" style='width:33.2pt'>$</td><td valign="bottom" style='width:43.55pt'>0.05</td><td valign="bottom" style='width:15.1pt'> </td><td valign="bottom" style='width:64.7pt'>-</td><td valign="bottom" style='width:34.55pt'>$</td><td valign="bottom" style='width:43.55pt'>n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:167.6pt'>Options expired</td><td valign="top" bgcolor="#DBE5F1" style='width:71.75pt'>(1,015,145)</td><td valign="bottom" bgcolor="#DBE5F1" style='width:33.2pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt'>0.34</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15.1pt'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:64.7pt'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:34.55pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:43.55pt'>n/a</td></tr><tr align="left"><td valign="top" style='width:167.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Options outstanding, ending</td><td valign="top" style='width:71.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>3,550,000</td><td valign="bottom" style='width:33.2pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.35</td><td valign="bottom" style='width:15.1pt'> </td><td valign="bottom" style='width:64.7pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>7,050,000</td><td valign="bottom" style='width:34.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" style='width:43.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.24</td></tr></table>

7050000

0.24

-2484855

-1015145

3550000

0.35

7050000

0.24

<table style='border-collapse:collapse;width:98.88%'><tr align="left"><td valign="bottom" style='width:35.36%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number of options outstandingand exercisable</td><td valign="bottom" style='width:14.26%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Exerciseprice</td><td valign="bottom" style='width:24.7%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Grant date</td><td valign="bottom" style='width:25.68%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Expiry date</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:35.36%;border-top:0.5pt solid #000000'>500,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:14.26%;border-top:0.5pt solid #000000'>$0.35</td><td valign="bottom" bgcolor="#DBE5F1" style='width:24.7%;border-top:0.5pt solid #000000'>August 5, 2015</td><td valign="bottom" bgcolor="#DBE5F1" style='width:25.68%;border-top:0.5pt solid #000000'>January 1, 2021</td></tr><tr align="left"><td valign="bottom" style='width:35.36%'>500,000</td><td valign="bottom" style='width:14.26%'>$0.35</td><td valign="bottom" style='width:24.7%'>August 5, 2015</td><td valign="bottom" style='width:25.68%'>April 1, 2021</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:35.36%'>500,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:14.26%'>$0.35</td><td valign="bottom" bgcolor="#DBE5F1" style='width:24.7%'>August 5, 2015</td><td valign="bottom" bgcolor="#DBE5F1" style='width:25.68%'>July 1, 2021</td></tr><tr align="left"><td valign="bottom" style='width:35.36%;border-bottom:0.5pt solid #000000'>2,050,000</td><td valign="bottom" style='width:14.26%;border-bottom:0.5pt solid #000000'>$0.35</td><td valign="bottom" style='width:24.7%;border-bottom:0.5pt solid #000000'>August 24, 2017</td><td valign="bottom" style='width:25.68%;border-bottom:0.5pt solid #000000'>August 23, 2022</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:35.36%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>3,550,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:14.26%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$0.35</td><td valign="bottom" bgcolor="#DBE5F1" style='width:24.7%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="bottom" bgcolor="#DBE5F1" style='width:25.68%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td></tr></table>

500000

2050000

3550000

0.35

<table style='border-collapse:collapse;width:95%'><tr align="left"><td valign="top" style='width:146.6pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:145.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Six months endedNovember 30, 2020</td><td valign="bottom" style='width:15pt;border-top:0.5pt solid #000000'> </td><td colspan="3" valign="bottom" style='width:136.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Year endedMay 31, 2020</td></tr><tr align="left"><td valign="top" style='width:146.6pt;border-bottom:0.5pt solid #000000'> </td><td valign="bottom" style='width:69.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofwarrants</td><td colspan="2" valign="bottom" style='width:75.55pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td><td valign="bottom" style='width:15pt'> </td><td valign="bottom" style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number ofwarrants</td><td colspan="2" valign="bottom" style='width:73.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Weightedaverageexercise price</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:146.6pt;border-top:0.5pt solid #000000'>Warrants outstanding, beginning</td><td valign="middle" bgcolor="#DBE5F1" style='width:69.85pt;border-top:0.5pt solid #000000'>18,864,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:54.75pt;border-top:0.5pt solid #000000'>0.94</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15pt'> </td><td valign="middle" bgcolor="#DBE5F1" style='width:63pt;border-top:0.5pt solid #000000'>20,297,565</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:53.05pt;border-top:0.5pt solid #000000'>0.78</td></tr><tr align="left"><td valign="top" style='width:146.6pt;border-top:0.5pt solid #000000'>Warrants issued</td><td valign="bottom" style='width:69.85pt;border-top:0.5pt solid #000000'>988,000</td><td valign="bottom" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" style='width:54.75pt;border-top:0.5pt solid #000000'>0.35/$0.50</td><td valign="bottom" style='width:15pt'> </td><td valign="middle" style='width:63pt;border-top:0.5pt solid #000000'>6,050,000</td><td valign="bottom" style='width:20.8pt;border-top:0.5pt solid #000000'>$</td><td valign="bottom" style='width:53.05pt;border-top:0.5pt solid #000000'>0.38</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:146.6pt'>Warrants exercised</td><td valign="bottom" bgcolor="#DBE5F1" style='width:69.85pt'>-</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:54.75pt'>n/a</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15pt'> </td><td valign="middle" bgcolor="#DBE5F1" style='width:63pt'>7,482,960</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:53.05pt'>0.05</td></tr><tr align="left"><td valign="top" style='width:146.6pt'>Warrants expired</td><td valign="middle" style='width:69.85pt'>1,480,000</td><td valign="bottom" style='width:20.8pt'>$</td><td valign="bottom" style='width:54.75pt'>1.50</td><td valign="bottom" style='width:15pt'> </td><td valign="middle" style='width:63pt'>-</td><td valign="bottom" style='width:20.8pt'>$</td><td valign="bottom" style='width:53.05pt'>n/a</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:146.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>Warrants outstanding, ending</td><td valign="middle" bgcolor="#DBE5F1" style='width:69.85pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>18,372,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:54.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.86</td><td valign="bottom" bgcolor="#DBE5F1" style='width:15pt'> </td><td valign="middle" bgcolor="#DBE5F1" style='width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>18,864,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:20.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>$</td><td valign="bottom" bgcolor="#DBE5F1" style='width:53.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>0.94</td></tr></table>

20297565

988000 6050000

7482960

1480000

18372605

18864605

<table style='border-collapse:collapse;width:100%;margin-left:0.9pt'><tr align="left"><td valign="bottom" style='width:21.74%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Number of warrantsexercisable</td><td valign="bottom" style='width:17.78%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Grant date</td><td valign="bottom" style='width:60.48%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'>Exercise price</td></tr><tr align="left"><td valign="top" bgcolor="#DBE5F1" style='width:21.74%;border-top:0.5pt solid #000000'>2,000,000</td><td valign="top" bgcolor="#DBE5F1" style='width:17.78%;border-top:0.5pt solid #000000'>March 3, 2016</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%;border-top:0.5pt solid #000000'>$0.75 expiring on March 3, 2021</td></tr><tr align="left"><td valign="top" style='width:21.74%'>9,094,605</td><td valign="top" style='width:17.78%'>October 12, 2016</td><td valign="top" style='width:60.48%'>$1.50 expiring on October 12, 2021</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%'>240,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%'>February 7, 2018</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%'>$1.50 expiring on February 7, 2021</td></tr><tr align="left"><td valign="bottom" style='width:21.74%'>3,950,000</td><td valign="bottom" style='width:17.78%'>June 24, 2019</td><td valign="top" style='width:60.48%'>$0.20 expiring on June 24, 2021</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%'>100,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%'>July 22, 2019</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%'>$0.20 expiring on July 22, 2021</td></tr><tr align="left"><td valign="bottom" style='width:21.74%'>1,000,000</td><td valign="bottom" style='width:17.78%'>January 29, 2020</td><td valign="top" style='width:60.48%'>$0.50 expiring on March 12, 2023</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%'>1,000,000</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%'>January 29, 2020</td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%'>$1.00 expiring on March 12, 2023</td></tr><tr align="left"><td valign="top" style='width:21.74%;border-bottom:0.5pt solid #000000'>988,000</td><td valign="top" style='width:17.78%;border-bottom:0.5pt solid #000000'>July 30, 2020</td><td valign="top" style='width:60.48%;border-bottom:0.5pt solid #000000'>$0.35 during the period from July 30, 2020 to January 30, 2021$0.50 during the period from January 30, 2021 to July 30, 2022</td></tr><tr align="left"><td valign="bottom" bgcolor="#DBE5F1" style='width:21.74%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'>18,372,605</td><td valign="bottom" bgcolor="#DBE5F1" style='width:17.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td><td valign="top" bgcolor="#DBE5F1" style='width:60.48%;border-top:0.5pt solid #000000;border-bottom:3px double #000000'> </td></tr></table>

2000000 9094605 240000 3950000 100000 1000000 1000000 988000 18372605 0001493712 2020-06-01 2020-11-30 0001493712 2020-11-30 0001493712 2019-11-30 0001493712 2021-01-14 0001493712 2020-05-31 0001493712 2020-09-01 2020-11-30 0001493712 2019-09-01 2019-11-30 0001493712 2019-06-01 2019-11-30 0001493712 us-gaap:SalesMember 2020-06-01 2020-11-30 0001493712 us-gaap:SalesMember 2020-09-01 2020-11-30 0001493712 us-gaap:SalesMember 2019-09-01 2019-11-30 0001493712 us-gaap:SalesMember 2019-06-01 2019-11-30 0001493712 fil:DistributionRights1Member 2020-06-01 2020-11-30 0001493712 fil:DistributionRights1Member 2020-09-01 2020-11-30 0001493712 fil:DistributionRights1Member 2019-09-01 2019-11-30 0001493712 fil:DistributionRights1Member 2019-06-01 2019-11-30 0001493712 us-gaap:CommonStockMember 2020-06-01 2020-11-30 0001493712 fil:ObligationToIssueSharesMember 2020-06-01 2020-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2020-06-01 2020-11-30 0001493712 fil:Reserves1Member 2020-06-01 2020-11-30 0001493712 us-gaap:RetainedEarningsMember 2020-06-01 2020-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-01 2020-11-30 0001493712 2019-05-31 0001493712 us-gaap:CommonStockMember 2019-05-31 0001493712 fil:ObligationToIssueSharesMember 2019-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2019-05-31 0001493712 fil:Reserves1Member 2019-05-31 0001493712 us-gaap:RetainedEarningsMember 2019-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-05-31 0001493712 us-gaap:CommonStockMember 2019-06-01 2019-11-30 0001493712 fil:ObligationToIssueSharesMember 2019-06-01 2019-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-11-30 0001493712 fil:Reserves1Member 2019-06-01 2019-11-30 0001493712 us-gaap:RetainedEarningsMember 2019-06-01 2019-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-01 2019-11-30 0001493712 us-gaap:CommonStockMember 2019-11-30 0001493712 fil:ObligationToIssueSharesMember 2019-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2019-11-30 0001493712 fil:Reserves1Member 2019-11-30 0001493712 us-gaap:RetainedEarningsMember 2019-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-30 0001493712 us-gaap:CommonStockMember 2020-05-31 0001493712 fil:ObligationToIssueSharesMember 2020-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2020-05-31 0001493712 fil:Reserves1Member 2020-05-31 0001493712 us-gaap:RetainedEarningsMember 2020-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-05-31 0001493712 us-gaap:CommonStockMember 2020-11-30 0001493712 fil:ObligationToIssueSharesMember 2020-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2020-11-30 0001493712 fil:Reserves1Member 2020-11-30 0001493712 us-gaap:RetainedEarningsMember 2020-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-11-30 0001493712 fil:DueToTheCeoMember 2020-11-30 0001493712 fil:DueToTheCeoMember 2020-05-31 0001493712 fil:DueToCfoMember 2020-11-30 0001493712 fil:DueToCfoMember 2020-05-31 0001493712 fil:DueToVpOfTechnologyAndOperationsMember 2020-11-30 0001493712 fil:DueToVpOfTechnologyAndOperationsMember 2020-05-31 0001493712 fil:DueToACompanyControlledByOurCooMember 2020-11-30 0001493712 fil:DueToMajorShareholderMember 2020-11-30 0001493712 fil:DueToMajorShareholderMember 2020-05-31 0001493712 fil:DueToACompanyControlledByTheCooAndAMajorShareholderMember 2020-11-30 0001493712 fil:DueToACompanyOfWhichTheCooIsADirectorOfMember 2020-11-30 0001493712 fil:ManagementFeesIncurredToACeoMember 2020-06-01 2020-11-30 0001493712 fil:ManagementFeesIncurredToACeoMember 2019-06-01 2019-11-30 0001493712 fil:ManagementFeesIncurredToTheCfoMember 2020-06-01 2020-11-30 0001493712 fil:ManagementFeesIncurredToTheCfoMember 2019-06-01 2019-11-30 0001493712 fil:ConsultingFeesIncurredToTheVpOfTechnologyAndOperationsMember 2020-06-01 2020-11-30 0001493712 fil:ConsultingFeesIncurredToTheVpOfTechnologyAndOperationsMember 2019-06-01 2019-11-30 0001493712 fil:ConsultingFeesIncurredToACompanyControlledByOurCooMember 2020-06-01 2020-11-30 0001493712 fil:RoyaltyIncurredToTheCompanyOfWhichTheCooIsADirectorOfMember 2020-06-01 2020-11-30 0001493712 fil:DevicesHeldForResaleMember 2020-11-30 0001493712 fil:DevicesHeldForResaleMember 2020-05-31 0001493712 fil:WorkInProgressIncludingUnfinishedEbalanceDevicesAndSuppliesMember 2020-11-30 0001493712 fil:WorkInProgressIncludingUnfinishedEbalanceDevicesAndSuppliesMember 2020-05-31 0001493712 fil:PrepaidExpensesMember 2020-11-30 0001493712 fil:PrepaidExpensesMember 2020-05-31 0001493712 fil:ReceivablesAssociatedWithGstCellMedxCanadaMember 2020-11-30 0001493712 fil:ReceivablesAssociatedWithGstCellMedxCanadaMember 2020-05-31 0001493712 2019-06-01 2020-05-31 0001493712 fil:CostOfEbalanceDevicesMember 2020-09-01 2020-11-30 0001493712 fil:CostOfEbalanceDevicesMember 2019-09-01 2019-11-30 0001493712 fil:CostOfEbalanceDevicesMember 2020-06-01 2020-11-30 0001493712 fil:CostOfEbalanceDevicesMember 2019-06-01 2019-11-30 0001493712 fil:RoyaltyPayableForEbalanceDevicesMember 2020-09-01 2020-11-30 0001493712 fil:RoyaltyPayableForEbalanceDevicesMember 2019-09-01 2019-11-30 0001493712 fil:RoyaltyPayableForEbalanceDevicesMember 2020-06-01 2020-11-30 0001493712 fil:RoyaltyPayableForEbalanceDevicesMember 2019-06-01 2019-11-30 0001493712 fil:ShortTermLoan1Member 2020-11-30 0001493712 fil:ShortTermLoan2Member 2020-11-30 0001493712 fil:ShortTermLoan3Member 2020-11-30 0001493712 fil:ShortTermLoan4Member 2020-11-30 0001493712 fil:ShortTermLoan5Member 2020-11-30 0001493712 fil:ShortTermLoan6Member 2020-11-30 0001493712 fil:ShortTermLoan7Member 2020-11-30 0001493712 fil:ShortTermLoan1Member 2020-05-31 0001493712 fil:ShortTermLoan2Member 2020-05-31 0001493712 fil:ShortTermLoan3Member 2020-05-31 0001493712 fil:ShortTermLoan4Member 2020-05-31 0001493712 fil:ShortTermLoan5Member 2020-05-31 0001493712 fil:N1ConvertibleLoansPayableMember 2020-06-01 2020-11-30 0001493712 fil:N1ConvertibleLoansPayableMember 2019-06-01 2019-11-30 0001493712 fil:N2NonConvertibleLoansPayableMember 2020-11-30 0001493712 fil:N2NonConvertibleLoansPayableMember 2020-05-31 0001493712 fil:N2NonConvertibleLoansPayableMember 2020-06-01 2020-11-30 0001493712 fil:N2NonConvertibleLoansPayableMember 2019-06-01 2019-11-30 0001493712 fil:N3RelatedPartyLoansPayableMember 2020-11-30 0001493712 fil:N3RelatedPartyLoansPayableMember 2020-05-31 0001493712 fil:N3RelatedPartyLoansPayableMember 2020-06-01 2020-11-30 0001493712 fil:N3RelatedPartyLoansPayableMember 2019-06-01 2019-11-30 0001493712 fil:N3RelatedPartyLoansPayableJuly9Member 2020-11-30 0001493712 fil:N3RelatedPartyLoansPayableJuly9Member 2020-06-01 2020-11-30 0001493712 fil:N4UnsecuredLineOfCreditWithRelatedPartyMember 2020-11-30 0001493712 fil:N4UnsecuredLineOfCreditWithRelatedPartyMember 2020-05-31 0001493712 fil:N4UnsecuredLineOfCreditWithRelatedPartyMember 2020-06-01 2020-11-30 0001493712 fil:N4UnsecuredLineOfCreditWithRelatedPartyMember 2019-06-01 2019-11-30 0001493712 fil:N5AdvancesPayableMember 2020-11-30 0001493712 fil:N5AdvancesPayableMember 2020-05-31 0001493712 fil:July302020IssuanceOfUnitsMember 2020-06-01 2020-11-30 0001493712 fil:July302020IssuanceOfUnitsMember 2019-06-01 2019-11-30 0001493712 fil:August132020IssuanceOfUnitsToA10ShareholderMember 2020-06-01 2020-11-30 0001493712 fil:August132020IssuanceOfUnitsToOurVpOfTechAndOperationsMember 2020-06-01 2020-11-30 0001493712 fil:OptionsExercisedMember 2020-06-01 2020-11-30 0001493712 fil:OptionsExpiredMember 2020-06-01 2020-11-30 0001493712 fil:OptionsGrantedAugust520151Member 2020-11-30 0001493712 fil:OptionsGrantedAugust520152Member 2020-11-30 0001493712 fil:OptionsGrantedAugust520153Member 2020-11-30 0001493712 fil:OptionsGrantedAugust520154Member 2020-11-30 0001493712 fil:WarrantsGrantedMar32016Member 2020-11-30 0001493712 fil:WarrantsGrantedOct16Member 2020-11-30 0001493712 fil:WarrantsGrantedFeb18Member 2020-11-30 0001493712 fil:WarrantsGrantedJune242019Member 2020-11-30 0001493712 fil:WarrantsGrantedJuly222019Member 2020-11-30 0001493712 fil:WarrantsGrantedJan2920201Member 2020-11-30 0001493712 fil:WarrantsGrantedJan2920202Member 2020-11-30 0001493712 fil:WarrantsGrantedJuly3020Member 2020-11-30 xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares EX-101.SCH 9 cmxc-20201130.xsd 000140 - Disclosure - Share Capital Disclosure link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Related Party Transactions Disclosure link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Other Current Assets Disclosure link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - Other Current Assets Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - Share Capital Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Organization and Nature of Operations link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - Share Capital Disclosure: Schedule of Stock Options Outstanding (Details) link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - Inventory Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Notes and Advances Payable Disclosure link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Equipment Disclosure link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Revenue Disclosure link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Inventory Disclosure link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Tables) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Share Capital Disclosure: Schedule of Stock Options Outstanding (Tables) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Organization and Nature of Operations (Details) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - Notes and Advances Payable Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Details) link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Details) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Details) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Tables) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 cmxc-20201130_cal.xml EX-101.DEF 11 cmxc-20201130_def.xml EX-101.LAB 12 cmxc-20201130_lab.xml Short-term Loan 5 Represents the Short-term Loan 5, during the indicated time period. Management fees incurred to the CFO Represents the Management fees incurred to the CFO, during the indicated time period. Schedule of Warrant Activity Represents the textual narrative disclosure of Schedule of Warrant Activity, during the indicated time period. Schedule of Revenue and Associated Costs Due to related parties: Adjustments to reconcile net loss to net cash used in operating activities Shares issued on exercise of options, value Stock issued for cash, shares Total operating expenses Common Stock, Shares Authorized STOCKHOLDERS' DEFICIT Entity Address, State or Province Amendment Description Current with reporting Number of warrants outstanding Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation Foreign exchange gain (loss), equipment Foreign exchange gain (loss), equipment Due to VP of Technology and Operations Represents the Due to VP of Technology and Operations, during the indicated time period. Related Party Transaction [Axis] Effects of foreign currency exchange on cash Shares issued on exercise of warrants, value Equity Balance, Shares Equity Balance, Shares Equity Balance, Shares Revenues Common Stock, Par or Stated Value Per Share Accumulated deficit Accumulated deficit Common stock, $0.001 par value, 300,000,000 shares authorized; 59,388,564 and 55,915,709 shares issued and outstanding at November 30, 2020 and at May 31, 2020, respectively Local Phone Number Entity File Number Period End date Warrants Granted Mar 3 2016 Represents the Warrants Granted Mar 3 2016, during the indicated time period. Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] (1) Convertible Loans Payable Represents the (1) Convertible Loans Payable, during the indicated time period. Short-term Debt, Type [Axis] Schedule of Stock Options Outstanding Notes and Advances Payable Disclosure Advances payable Cash flows used in investing activities Cost of goods sold Sales Total stockholders' deficit Total stockholders' deficit Equity Balance Equity Balance Additional paid-in capital Document Quarterly Report Options exercised Represents the Options exercised, during the indicated time period. Due to a company controlled by our COO Represents the Due to a company controlled by our COO, during the indicated time period. Proceeds from subscription to shares Liabilities {1} Liabilities Equipment Equipment, book value Emerging Growth Company August 13, 2020 Issuance of Units to our VP of Tech and Operations Represents the August 13, 2020 Issuance of Units to our VP of Tech and Operations, during the indicated time period. Effective interest rate Short-term Loan 1 Represents the Short-term Loan 1, during the indicated time period. Short-term Debt, Type Inventory [Axis] Due from related parties Due to a company of which the COO is a director of Represents the Due to a company of which the COO is a director of, during the indicated time period. Share Capital Disclosure Inventory Disclosure Proceeds from exercise of warrants for debt Net cash used in operating activities Net cash used in operating activities Unearned revenue: Accrued liabilities: Other current assets: Other current assets: Unrealized foreign exchange Stock issued for cash, value Operating expenses Reserves Represents the monetary amount of Reserves, as of the indicated date. Entity Incorporation, State or Country Code July 30, 2020 Issuance of Units Represents the July 30, 2020 Issuance of Units, during the indicated time period. Notes and advances payable {1} Notes and advances payable Short-term Loan 7 Represents the Short-term Loan 7, during the indicated time period. Inventory {1} Inventory Due to a company controlled by the COO and a major shareholder Represents the Due to a company controlled by the COO and a major shareholder, during the indicated time period. Related Party Transactions Disclosure Revenues {1} Revenues Distribution rights Represents the Distribution rights, during the indicated time period. Shell Company Options oustanding and excersiable Short-term Loan 2 Represents the Short-term Loan 2, during the indicated time period. Increase (decrease) in equipment Increase (decrease) in equipment Asset Class Due to the CEO Represents the Due to the CEO, during the indicated time period. Tables/Schedules Other Current Assets Disclosure Acquisition of equipment Acquisition of equipment Inventory: Inventory: Non-cash IR fees Represents the monetary amount of Non-cash IR fees, during the indicated time period. Equity Component Obligation to Issue Shares Represents the Obligation to Issue Shares, during the indicated time period. Interest Interest Interest expense Total liabilities and stockholders' deficit Total liabilities and stockholders' deficit Total liabilities Total liabilities Accrued liabilities Accounts payable Warrants Granted June 24 2019 Represents the Warrants Granted June 24 2019, during the indicated time period. Options outsanding, weighted average exercise price August 13, 2020 Issuance of Units to a 10% shareholder Represents the August 13, 2020 Issuance of Units to a 10% shareholder, during the indicated time period. Accrued interest/accretion Amortization {1} Amortization Asset Class [Axis] Due to related parties {1} Due to related parties Due to major shareholder Represents the Due to major shareholder, during the indicated time period. Due to CFO Represents the Due to CFO, during the indicated time period. Accounts payable: Cash flows used in operating activities Shares issued on exercise of options, shares Reserves {1} Reserves Represents the Reserves, during the indicated time period. Additional Paid-in Capital Equity Components [Axis] Common Stock, Shares, Issued Total current assets Total current assets Document Transition Report Well-known Seasoned Issuer Trading Symbol Principal outstanding Short-term Loan 6 Represents the Short-term Loan 6, during the indicated time period. Management fees incurred the CEO Represents the Management fees incurred the CEO, during the indicated time period. Proceeds from notes payable Net cash used in investing activities Net cash used in investing activities Weighted Average Number of Shares Outstanding, Basic and Diluted Foreign currency translation Income (loss) Foreign currency translation Income (loss) Other current assets Current assets Ex Transition Period Registrant Name Details Warrants Granted Jan 29, 2020(2) Represents the Warrants Granted Jan 29, 2020(2), during the indicated time period. Options granted August 5, 2015(3) Represents the Options granted August 5, 2015(3), during the indicated time period. Stock options outstanding Options expired Represents the Options expired, during the indicated time period. (3) Related Party Loans Payable Represents the (3) Related Party Loans Payable, during the indicated time period. Equipment Disclosure Net income (loss) for the period Net income (loss) for the period Comprehensive loss LIABILITIES AND STOCKHOLDERS' DEFICIT Total assets Total assets Inventory SEC Form (3) Related Party Loans Payable - July 9 Represents the (3) Related Party Loans Payable - July 9, during the indicated time period. Work in progress, including unfinished eBalance devices and supplies Represents the Work in progress, including unfinished eBalance devices and supplies, during the indicated time period. Increase (decrease) in cash Increase (decrease) in cash Net cash provided by financing activities Net cash provided by financing activities Accumulated other comprehensive income (loss) Document Fiscal Year Focus Entity Address, Postal Zip Code Interactive Data Current Filer Category Number of warrants exercisable Number of warrants exercisable Warrants Granted Jan 29, 2020(1) Represents the Warrants Granted Jan 29, 2020(1), during the indicated time period. Warrants Granted Oct 12 2016 Represents the Warrants Granted Oct 12 2016, during the indicated time period. Warrants expired (2) Non-convertible Loans Payable Represents the (2) Non-convertible Loans Payable, during the indicated time period. Short-term Loan 3 Represents the Short-term Loan 3, during the indicated time period. Notes Proceeds from exercise of options for debt Retained Earnings Research and development costs General and administrative expenses Consulting fees Gross margin Statement Tax Identification Number (TIN) Warrants granted July 30, 2020 Represents the Warrants granted July 30, 2020, during the indicated time period. Warrants Granted Feb 7 2018 Represents the Warrants Granted Feb 7 2018, during the indicated time period. Options granted August 5, 2015(4) Represents the Options granted August 5, 2015(4), during the indicated time period. Devices held for resale Represents the Devices held for resale, during the indicated time period. Related Party Transaction Changes in operating assets and liabilities AOCI Attributable to Parent Notes and advances payable Amendment Flag Entity Address, City or Town Voluntary filer Trading Exchange Exercise price (options) Exercise price (options) Stock Option shares, increase (decrease) (5) Advances Payable Represents the (5) Advances Payable, during the indicated time period. Receivables associated with GST Cell MedX Canada Represents the Receivables associated with GST Cell MedX Canada, during the indicated time period. Consulting fees incurred to a company controlled by our COO Represents the Consulting fees incurred to a company controlled by our COO, during the indicated time period. Schedule of Warrant Details Schedule of Short-term Loans and Advances Outstanding Cash flows from financing activities City Area Code Public Float Registrant CIK Warrants Granted July 22 2019 Represents the Warrants Granted July 22 2019, during the indicated time period. Warrants issued Issuance of warrants to acquire common stock (4) Unsecured Line of Credit with Related Party Represents the (4) Unsecured Line of Credit with Related Party, during the indicated time period. Cost of eBalance devices Represents the Cost of eBalance devices, during the indicated time period. Change in book value of the equipment Schedule of Transactions with Related Parties Tabular Disclosure Cash, beginning Cash, beginning Cash, ending Translation to reporting currency EX-101.PRE 13 cmxc-20201130_pre.xml XML 14 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Nov. 30, 2020	Jan. 14, 2021
Details
Registrant CIK	0001493712
Fiscal Year End	--05-31
Registrant Name	Cell MedX Corp.
SEC Form	10-Q
Period End date	Nov. 30, 2020
Tax Identification Number (TIN)	38-3939625
Number of common stock shares outstanding		59,388,564
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	false
Small Business	true
Emerging Growth Company	false
Entity File Number	000-54500
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	123 W. Nye Ln, Suite 446
Entity Address, City or Town	Carson City
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89706
City Area Code	844
Local Phone Number	238-2692
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false

XML 15 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Nov. 30, 2020	May 31, 2020
Current assets
Cash	$ 21,784	$ 45,090
Inventory	53,051	51,886
Other current assets	20,748	60,367
Total current assets	95,583	157,343
Equipment	2,138	1,836
Total assets	97,721	159,179
Liabilities
Accounts payable	390,709	908,783
Accrued liabilities	10,350	34,565
Due to related parties	734,237	233,738
Notes and advances payable	646,173	502,437
Total liabilities	1,781,469	1,679,523
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 300,000,000 shares authorized; 59,388,564 and 55,915,709 shares issued and outstanding at November 30, 2020 and at May 31, 2020, respectively	59,389	55,916
Additional paid-in capital	6,355,923	5,988,153
Obligation to issue shares	0	80,000
Reserves	366,493	366,493
Accumulated deficit	(8,440,058)	(8,049,520)
Accumulated other comprehensive income (loss)	(25,495)	38,614
Total stockholders' deficit	(1,683,748)	(1,520,344)
Total liabilities and stockholders' deficit	$ 97,721	$ 159,179

XML 16 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares	Nov. 30, 2020	May 31, 2020
Details
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares, Issued	59,388,564	55,915,709

XML 17 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Nov. 30, 2020	Nov. 30, 2019
Revenues
Revenues	$ 1,871	$ 10,237	$ 3,338	$ 30,538
Cost of goods sold	988	522	1,357	5,897
Gross margin	883	9,715	1,981	24,641
Operating expenses
Amortization	632	545	1,368	813
Consulting fees	62,447	61,728	139,387	150,999
Distribution expenses	0	19,173	261	35,620
General and administrative expenses	80,723	132,080	113,503	218,642
Research and development costs	38,538	95,894	123,675	156,607
Total operating expenses	182,340	309,420	378,194	562,681
Other items
Interest	(7,879)	(3,783)	(14,325)	(10,735)
Net loss	(189,336)	(303,488)	(390,538)	(548,775)
Foreign currency translation Income (loss)	(7,227)	453	(64,109)	(6,488)
Comprehensive loss	$ (196,563)	$ (303,035)	$ (454,647)	$ (555,263)
Earnings Per Share, Basic and Diluted	$ (0.00)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted Average Number of Shares Outstanding, Basic and Diluted	59,388,564	55,075,636	58,054,426	51,139,321
Sales
Revenues
Revenues	$ 1,871	$ 757	$ 3,338	$ 12,100
Distribution rights
Revenues
Revenues	$ 0	$ 9,480	$ 0	$ 18,438

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Obligation to Issue Shares	Additional Paid-in Capital	Reserves	Retained Earnings	AOCI Attributable to Parent	Total
Equity Balance at May. 31, 2019	$ 44,283	$ 0	$ 5,109,866	$ 14,400	$ (6,956,822)	$ 15,714	$ (1,772,559)
Equity Balance, Shares at May. 31, 2019	44,282,749
Stock issued for cash, value	$ 4,050	0	481,950	0	0	0	486,000
Stock issued for cash, shares	4,050,000
Shares issued on exercise of warrants, value	$ 7,483	(374,148)	366,665	0	0	0	0
Shares issued on exercise of warrants, shares	7,482,960
Net income (loss) for the period	$ 0	0	0	0	(548,775)	0	(548,775)
Translation to reporting currency	$ 0	0	0	0	0	(6,488)	(6,488)
Equity Balance, Shares at Nov. 30, 2019	55,815,709
Equity Balance at Nov. 30, 2019	$ 55,816	0	5,958,481	14,400	(7,505,597)	9,226	(1,467,674)
Equity Balance at May. 31, 2020	$ 55,916	80,000	5,988,153	366,493	(8,049,520)	38,614	(1,520,344)
Equity Balance, Shares at May. 31, 2020	55,915,709
Stock issued for cash, value	$ 988	(80,000)	246,012	0	0	0	167,000
Stock issued for cash, shares	988,000
Shares issued on exercise of options, value	$ 2,485	0	121,758	0	0	0	124,243
Shares issued on exercise of options, shares	2,484,855
Net income (loss) for the period	$ 0	0	0	0	(390,538)	0	(390,538)
Translation to reporting currency	$ 0	0	0	0	0	(64,109)	(64,109)
Equity Balance, Shares at Nov. 30, 2020	59,388,564
Equity Balance at Nov. 30, 2020	$ 59,389	$ 0	$ 6,355,923	$ 366,493	$ (8,440,058)	$ (25,495)	$ (1,683,748)

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Nov. 30, 2020	Nov. 30, 2019
Cash flows used in operating activities
Net loss	$ (390,538)	$ (548,775)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable	14,325	10,735
Amortization	1,368	813
Unrealized foreign exchange	(48,686)	(2,909)
Non-cash IR fees	11,000	0
Changes in operating assets and liabilities
Inventory:	2,070	(3,293)
Other current assets:	29,937	11,849
Accounts payable:	24,776	58,529
Accrued liabilities:	(24,545)	2,823
Unearned revenue:	0	(244)
Due to related parties:	66,520	(8,898)
Net cash used in operating activities	(313,773)	(479,370)
Cash flows used in investing activities
Acquisition of equipment	(1,574)	(2,463)
Net cash used in investing activities	(1,574)	(2,463)
Cash flows from financing activities
Advances payable	0	15,000
Proceeds from notes payable	125,773	197,650
Proceeds from subscription to shares	167,000	486,000
Net cash provided by financing activities	292,773	698,650
Effects of foreign currency exchange on cash	(732)	1,002
Increase (decrease) in cash	(23,306)	217,819
Cash, beginning	45,090	57,172
Cash, ending	21,784	274,991
Non-cash financing transactions:
Proceeds from exercise of warrants for debt	0	374,148
Proceeds from exercise of options for debt	$ 124,243	$ 0

XML 20 R7.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations

6 Months Ended

Nov. 30, 2020

Notes

Organization and Nature of Operations

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Unaudited Interim Financial Statements

Going concern

Risks related to the rapid expansion of the COVID-19 pandemic

XML 21 R8.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure

6 Months Ended

Nov. 30, 2020

Notes

Related Party Transactions Disclosure

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than advances and notes payable to related parties (Note 7) at November 30, 2020, and at May 31, 2020:

	November 30, 2020		May 31, 2020
Due to the Chief Executive Officer (“CEO”)	$	109,200	$	103,200
Due to the Chief Financial Officer (“CFO”)		7,966		9,533
Due to the Vice President (“VP”), Technology and Operations		-		34,219
Due (from) the Vice President (“VP”), Technology and Operations		3,424		-
Due to a company controlled by the Chief Operating Officer (“COO”)⁽¹⁾		618,122		n/a
Due to a major shareholder		-		86,786
Due to a company controlled by the COO and major shareholder		2,250		n/a
Due to a company of which the COO is a director of		123		n/a
Due to related parties	$	734,237	$	233,738

(1)John da Costa was appointed Director and Chief Operating Officer of the Company on June 8, 2020, as of that date any company controlled by Mr. Da Costa is considered to be a related entity.

The amounts due to related parties are unsecured, due on demand and bear no interest.

During the six-month periods ended November 30, 2020 and 2019, the Company had the following transactions with related parties:

	November 30, 2020		November 30, 2019
Management fees incurred to the CEO	$	6,000	$	21,600
Management fees incurred to the CFO		13,500		6,000
Consulting fees incurred to the VP, Technology and Operations		22,337		22,593
Consulting fees incurred to the company controlled by the COO		77,378		n/a
Royalty incurred to the company of which the COO is a director of		53		n/a
Total transactions with related parties	$	119,268	$	50,193

XML 22 R9.htm IDEA: XBRL DOCUMENT

Inventory Disclosure

6 Months Ended

Nov. 30, 2020

Notes

Inventory Disclosure

NOTE 3 - INVENTORY

XML 23 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets Disclosure

6 Months Ended

Nov. 30, 2020

Notes

Other Current Assets Disclosure

NOTE 4 - OTHER CURRENT ASSETS

XML 24 R11.htm IDEA: XBRL DOCUMENT

Equipment Disclosure

6 Months Ended

Nov. 30, 2020

Notes

Equipment Disclosure

NOTE 5 - EQUIPMENT

Changes in the net book value of the equipment at November 30, 2020 and May 31, 2020 are as follows:

	November 30, 2020		May 31, 2020
Book value, beginning of the period	$	1,836	$	1,281
Changes during the period		1,574		2,463
Amortization		1,368		1,846
Foreign exchange		96		(62)
Book value, end of the period	$	2,138	$	1,836

XML 25 R12.htm IDEA: XBRL DOCUMENT

Revenue Disclosure

6 Months Ended

Nov. 30, 2020

Notes

Revenue Disclosure

NOTE 6 - REVENUE

	Three months ended November 30,				Six months ended November 30,
	2020		2019		2020		2019
Sales of eBalance^® devices	$	-	$	757	$	-	$	12,100
Monthly subscriptions		1,871		-		3,338		-
Cost of eBalance^® devices and services		(958)		(434)		(1,304)		(4,485)
Royalty payable		(30)		(88)		(53)		(1,412)
Distribution rights		-		9,480		-		18,438
Gross margin	$	883	$	9,715	$	1,981	$	24,641

XML 26 R13.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure

6 Months Ended

Nov. 30, 2020

Notes

Notes and Advances Payable Disclosure

NOTE 7 - NOTES AND ADVANCES PAYABLE

The tables below summarize the short-term loans and advances outstanding as at November 30, 2020, and May 31, 2020:

As at November 30, 2020
Principal Outstanding		Interest Rate per Annum		Accrued Interest⁽⁶⁾		Total Book Value
$	327,650	6%	Convertible⁽¹⁾	$	21,039	$	348,689
	141,065	6%	Non-convertible⁽²⁾		5,942		147,007
	7,045	6%	Related party⁽³⁾		552		7,597
	35,606	6%	Related party⁽⁴⁾		2,789		38,395
	15,426	6%	Related party⁽³⁾		369		15,795
	40,440	0%	Related party advances⁽⁵⁾		-		40,440
	48,250	0%	Advances⁽⁵⁾		-		48,250
$	615,482			$	30,691	$	646,173

As at May 31, 2020
Principal Outstanding		Interest Rate per Annum		Accrued Interest⁽⁶⁾		Total Book Value
$	327,650	6%	Convertible⁽¹⁾	$	10,731	$	338,381
	28,630	6%	Non-convertible⁽²⁾		3,464		32,094
	6,625	6%	Related party⁽³⁾		308		6,933
	35,606	6%	Related party⁽⁴⁾		1,654		37,260
	87,769	0%	Advances⁽⁵⁾		-		87,769
$	486,280			$	16,157	$	502,437

(1) Convertible Loans Payable

During the six-month period ended November 30, 2020, the Company recorded $10,308 in interest on the convertible loans payable (2020 - $2,668).

(2) Non-convertible Loans Payable

During the six-month period ended November 30, 2020, the Company recorded $2,303 in interest on these loans (2020 - $951).

(3) Related Party Loans Payable

(4) Unsecured Line of Credit with Related Party

(5) Advances Payable

(6) Interest Expense

During the six-month period ended November 30, 2020, the Company recorded a total of $14,325 (2020 - $10,735) in interest expense associated with its liabilities under the notes and advances payable.

XML 27 R14.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure

6 Months Ended

Nov. 30, 2020

Notes

Share Capital Disclosure

NOTE 8 - SHARE CAPITAL

Options

The changes in the number of stock options outstanding during the six-month period ended November 30, 2020, and for the year ended May 31, 2020, are as follows:

	Six months ended November 30, 2020			Year ended May 31, 2020
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	7,050,000	$	0.24	7,050,000	$	0.24
Options exercised	(2,484,855)	$	0.05	-	$	n/a
Options expired	(1,015,145)	$	0.34	-	$	n/a
Options outstanding, ending	3,550,000	$	0.35	7,050,000	$	0.24

Details of options outstanding and exercisable as at November 30, 2020, are as follows:

Number of options outstanding and exercisable	Exercise price	Grant date	Expiry date
500,000	$0.35	August 5, 2015	January 1, 2021
500,000	$0.35	August 5, 2015	April 1, 2021
500,000	$0.35	August 5, 2015	July 1, 2021
2,050,000	$0.35	August 24, 2017	August 23, 2022
3,550,000	$0.35

At November 30, 2020, the weighted average remaining contractual life of the stock options outstanding was 1.14 years.

Warrants

The changes in the number of warrants outstanding during the six-month period ended November 30, 2020, and for the year ended May 31, 2020, are as follows:

	Six months ended November 30, 2020			Year ended May 31, 2020
	Number of warrants	Weighted average exercise price		Number of warrants	Weighted average exercise price
Warrants outstanding, beginning	18,864,605	$	0.94	20,297,565	$	0.78
Warrants issued	988,000	$	0.35/$0.50	6,050,000	$	0.38
Warrants exercised	-	$	n/a	7,482,960	$	0.05
Warrants expired	1,480,000	$	1.50	-	$	n/a
Warrants outstanding, ending	18,372,605	$	0.86	18,864,605	$	0.94

Details of warrants outstanding as at November 30, 2020, are as follows:

Number of warrants exercisable	Grant date	Exercise price
2,000,000	March 3, 2016	$0.75 expiring on March 3, 2021
9,094,605	October 12, 2016	$1.50 expiring on October 12, 2021
240,000	February 7, 2018	$1.50 expiring on February 7, 2021
3,950,000	June 24, 2019	$0.20 expiring on June 24, 2021
100,000	July 22, 2019	$0.20 expiring on July 22, 2021
1,000,000	January 29, 2020	$0.50 expiring on March 12, 2023
1,000,000	January 29, 2020	$1.00 expiring on March 12, 2023
988,000	July 30, 2020	$0.35 during the period from July 30, 2020 to January 30, 2021 $0.50 during the period from January 30, 2021 to July 30, 2022
18,372,605

At November 30, 2020, the weighted average life of the warrants was 0.86 years.

XML 28 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Amounts Due to Related Parties

	November 30, 2020		May 31, 2020
Due to the Chief Executive Officer (“CEO”)	$	109,200	$	103,200
Due to the Chief Financial Officer (“CFO”)		7,966		9,533
Due to the Vice President (“VP”), Technology and Operations		-		34,219
Due (from) the Vice President (“VP”), Technology and Operations		3,424		-
Due to a company controlled by the Chief Operating Officer (“COO”)⁽¹⁾		618,122		n/a
Due to a major shareholder		-		86,786
Due to a company controlled by the COO and major shareholder		2,250		n/a
Due to a company of which the COO is a director of		123		n/a
Due to related parties	$	734,237	$	233,738

XML 29 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Transactions with Related Parties

	November 30, 2020		November 30, 2019
Management fees incurred to the CEO	$	6,000	$	21,600
Management fees incurred to the CFO		13,500		6,000
Consulting fees incurred to the VP, Technology and Operations		22,337		22,593
Consulting fees incurred to the company controlled by the COO		77,378		n/a
Royalty incurred to the company of which the COO is a director of		53		n/a
Total transactions with related parties	$	119,268	$	50,193

XML 30 R17.htm IDEA: XBRL DOCUMENT

Equipment Disclosure: Change in book value of the equipment (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Change in book value of the equipment

	November 30, 2020		May 31, 2020
Book value, beginning of the period	$	1,836	$	1,281
Changes during the period		1,574		2,463
Amortization		1,368		1,846
Foreign exchange		96		(62)
Book value, end of the period	$	2,138	$	1,836

XML 31 R18.htm IDEA: XBRL DOCUMENT

Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Revenue and Associated Costs

	Three months ended November 30,				Six months ended November 30,
	2020		2019		2020		2019
Sales of eBalance^® devices	$	-	$	757	$	-	$	12,100
Monthly subscriptions		1,871		-		3,338		-
Cost of eBalance^® devices and services		(958)		(434)		(1,304)		(4,485)
Royalty payable		(30)		(88)		(53)		(1,412)
Distribution rights		-		9,480		-		18,438
Gross margin	$	883	$	9,715	$	1,981	$	24,641

XML 32 R19.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Short-term Loans and Advances Outstanding

As at November 30, 2020
Principal Outstanding		Interest Rate per Annum		Accrued Interest⁽⁶⁾		Total Book Value
$	327,650	6%	Convertible⁽¹⁾	$	21,039	$	348,689
	141,065	6%	Non-convertible⁽²⁾		5,942		147,007
	7,045	6%	Related party⁽³⁾		552		7,597
	35,606	6%	Related party⁽⁴⁾		2,789		38,395
	15,426	6%	Related party⁽³⁾		369		15,795
	40,440	0%	Related party advances⁽⁵⁾		-		40,440
	48,250	0%	Advances⁽⁵⁾		-		48,250
$	615,482			$	30,691	$	646,173

As at May 31, 2020
Principal Outstanding		Interest Rate per Annum		Accrued Interest⁽⁶⁾		Total Book Value
$	327,650	6%	Convertible⁽¹⁾	$	10,731	$	338,381
	28,630	6%	Non-convertible⁽²⁾		3,464		32,094
	6,625	6%	Related party⁽³⁾		308		6,933
	35,606	6%	Related party⁽⁴⁾		1,654		37,260
	87,769	0%	Advances⁽⁵⁾		-		87,769
$	486,280			$	16,157	$	502,437

XML 33 R20.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Option Activity (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Stock Option Activity

	Six months ended November 30, 2020			Year ended May 31, 2020
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	7,050,000	$	0.24	7,050,000	$	0.24
Options exercised	(2,484,855)	$	0.05	-	$	n/a
Options expired	(1,015,145)	$	0.34	-	$	n/a
Options outstanding, ending	3,550,000	$	0.35	7,050,000	$	0.24

XML 34 R21.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Options Outstanding (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Stock Options Outstanding

Number of options outstanding and exercisable	Exercise price	Grant date	Expiry date
500,000	$0.35	August 5, 2015	January 1, 2021
500,000	$0.35	August 5, 2015	April 1, 2021
500,000	$0.35	August 5, 2015	July 1, 2021
2,050,000	$0.35	August 24, 2017	August 23, 2022
3,550,000	$0.35

XML 35 R22.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Activity (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Warrant Activity

	Six months ended November 30, 2020			Year ended May 31, 2020
	Number of warrants	Weighted average exercise price		Number of warrants	Weighted average exercise price
Warrants outstanding, beginning	18,864,605	$	0.94	20,297,565	$	0.78
Warrants issued	988,000	$	0.35/$0.50	6,050,000	$	0.38
Warrants exercised	-	$	n/a	7,482,960	$	0.05
Warrants expired	1,480,000	$	1.50	-	$	n/a
Warrants outstanding, ending	18,372,605	$	0.86	18,864,605	$	0.94

XML 36 R23.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Details (Tables)

6 Months Ended

Nov. 30, 2020

Tables/Schedules

Schedule of Warrant Details

Number of warrants exercisable	Grant date	Exercise price
2,000,000	March 3, 2016	$0.75 expiring on March 3, 2021
9,094,605	October 12, 2016	$1.50 expiring on October 12, 2021
240,000	February 7, 2018	$1.50 expiring on February 7, 2021
3,950,000	June 24, 2019	$0.20 expiring on June 24, 2021
100,000	July 22, 2019	$0.20 expiring on July 22, 2021
1,000,000	January 29, 2020	$0.50 expiring on March 12, 2023
1,000,000	January 29, 2020	$1.00 expiring on March 12, 2023
988,000	July 30, 2020	$0.35 during the period from July 30, 2020 to January 30, 2021 $0.50 during the period from January 30, 2021 to July 30, 2022
18,372,605

XML 37 R24.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations (Details) - USD ($)	Nov. 30, 2020	May 31, 2020
Details
Accumulated deficit	$ 8,440,058	$ 8,049,520

XML 38 R25.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) - USD ($)	Nov. 30, 2020	May 31, 2020
Due to related parties	$ 734,237	$ 233,738
Due to the CEO
Due to related parties	109,200	103,200
Due to CFO
Due to related parties	7,966	9,533
Due to VP of Technology and Operations
Due to related parties	0	34,219
Due from related parties	3,424	0
Due to a company controlled by our COO
Due to related parties	618,122
Due to major shareholder
Due to related parties	0	$ 86,786
Due to a company controlled by the COO and a major shareholder
Due to related parties	2,250
Due to a company of which the COO is a director of
Due to related parties	$ 123

XML 39 R26.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) - USD ($)	6 Months Ended
	Nov. 30, 2020	Nov. 30, 2019
Transactions with related parties	$ 119,268	$ 50,193
Management fees incurred the CEO
Transactions with related parties	6,000	21,600
Management fees incurred to the CFO
Transactions with related parties	13,500	6,000
Consulting fees incurred to the VP of Technology and Operations
Transactions with related parties	22,337	$ 22,593
Consulting fees incurred to a company controlled by our COO
Transactions with related parties	77,378
Royalty incurred to the company of which the COO is a director of
Transactions with related parties	$ 53

XML 40 R27.htm IDEA: XBRL DOCUMENT

Inventory Disclosure (Details) - USD ($)	Nov. 30, 2020	May 31, 2020
Inventory	$ 53,051	$ 51,886
Devices held for resale
Inventory	29,290	29,405
Work in progress, including unfinished eBalance devices and supplies
Inventory	$ 23,761	$ 22,481

XML 41 R28.htm IDEA: XBRL DOCUMENT

Other Current Assets Disclosure (Details) - USD ($)	Nov. 30, 2020	May 31, 2020
Other current assets	$ 20,748	$ 60,367
Prepaid expenses
Other current assets	14,325	44,021
Receivables associated with GST Cell MedX Canada
Other current assets	$ 6,423	$ 16,346

XML 42 R29.htm IDEA: XBRL DOCUMENT

Equipment Disclosure: Change in book value of the equipment (Details) - USD ($)	6 Months Ended	12 Months Ended
	Nov. 30, 2020	May 31, 2020
Details
Increase (decrease) in equipment	$ 1,574	$ 2,463
Amortization	1,368	1,846
Foreign exchange gain (loss), equipment	96	(62)
Equipment, book value	$ 2,138	$ 1,836

XML 43 R30.htm IDEA: XBRL DOCUMENT

Revenue Disclosure: Schedule of Revenue and Associated Costs (Details) - USD ($)	3 Months Ended		6 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Nov. 30, 2020	Nov. 30, 2019
Revenues	$ 1,871	$ 10,237	$ 3,338	$ 30,538
Cost of goods sold	988	522	1,357	5,897
Gross margin	883	9,715	1,981	24,641
Sales
Revenues	1,871	757	3,338	12,100
Cost of eBalance devices
Cost of goods sold	958	434	1,304	4,485
Royalty payable for eBalance devices
Cost of goods sold	30	88	53	1,412
Distribution rights
Revenues	$ 0	$ 9,480	$ 0	$ 18,438

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 44 R31.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Details) - USD ($)	Nov. 30, 2020	May 31, 2020
Principal outstanding	$ 615,482	$ 486,280
Accrued interest/accretion	30,691	16,157
Notes and advances payable	646,173	502,437
Short-term Loan 1
Principal outstanding	$ 327,650	$ 327,650
Effective interest rate	6.00%	6.00%
Accrued interest/accretion	$ 21,039	$ 10,731
Notes and advances payable	348,689	338,381
Short-term Loan 2
Principal outstanding	$ 141,065	$ 28,630
Effective interest rate	6.00%	6.00%
Accrued interest/accretion	$ 5,942	$ 3,464
Notes and advances payable	147,007	32,094
Short-term Loan 3
Principal outstanding	$ 7,045	$ 6,625
Effective interest rate	6.00%	6.00%
Accrued interest/accretion	$ 552	$ 308
Notes and advances payable	7,597	6,933
Short-term Loan 4
Principal outstanding	$ 35,606	$ 35,606
Effective interest rate	6.00%	6.00%
Accrued interest/accretion	$ 2,789	$ 1,654
Notes and advances payable	38,395	37,260
Short-term Loan 5
Principal outstanding	$ 15,426	$ 87,769
Effective interest rate	6.00%	0.00%
Accrued interest/accretion	$ 369	$ 0
Notes and advances payable	15,795	$ 87,769
Short-term Loan 6
Principal outstanding	$ 40,440
Effective interest rate	0.00%
Accrued interest/accretion	$ 0
Notes and advances payable	40,440
Short-term Loan 7
Principal outstanding	$ 48,250
Effective interest rate	0.00%
Accrued interest/accretion	$ 0
Notes and advances payable	$ 48,250

XML 45 R32.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure (Details) - USD ($)	3 Months Ended		6 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Nov. 30, 2020	Nov. 30, 2019	May 31, 2020
Interest expense	$ 7,879	$ 3,783	$ 14,325	$ 10,735
Notes and advances payable	646,173		646,173		$ 502,437
(1) Convertible Loans Payable
Interest expense			10,308	2,668
(2) Non-convertible Loans Payable
Interest expense			2,303	951
Notes and advances payable	147,007		147,007		32,094
(3) Related Party Loans Payable
Interest expense			219	2,425
Notes and advances payable	7,597		7,597		6,933
(3) Related Party Loans Payable - July 9
Interest expense			360
Notes and advances payable	14,773		14,773
(4) Unsecured Line of Credit with Related Party
Interest expense			1,135	$ 4,691
Notes and advances payable	38,395		38,395		37,260
(5) Advances Payable
Notes and advances payable	$ 88,690		$ 88,690		$ 87,769

XML 46 R33.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure (Details) - USD ($)	6 Months Ended
Share Capital Disclosure (Details) - USD ($)	Nov. 30, 2020	Nov. 30, 2019
Stock issued for cash, value	$ 167,000	$ 486,000
July 30, 2020 Issuance of Units
Stock issued for cash, shares	988,000
Stock issued for cash, value		$ 80,000
Units Offered, Description	Each unit consisted of one common share of the Company and one warrant allowing its holder to acquire an additional common share at $0.35 until January 30, 2021, and at $0.50 per share from January 30, 2021 to July 30, 2022
August 13, 2020 Issuance of Units to a 10% shareholder
Stock issued for cash, shares	1,250,000
August 13, 2020 Issuance of Units to our VP of Tech and Operations
Stock issued for cash, shares	1,234,855

XML 47 R34.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Option Activity (Details) - $ / shares	6 Months Ended
	Nov. 30, 2020	May 31, 2020	May 31, 2019
Stock options outstanding	3,550,000	7,050,000	7,050,000
Options outsanding, weighted average exercise price	$ 0.35	$ 0.24	$ 0.24
Options exercised
Stock Option shares, increase (decrease)	(2,484,855)
Options expired
Stock Option shares, increase (decrease)	(1,015,145)

XML 48 R35.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Options Outstanding (Details)	6 Months Ended
	Nov. 30, 2020 $ / shares shares
Options oustanding and excersiable	3,550,000
Exercise price (options) \| $ / shares	$ 0.35
Options granted August 5, 2015(1)
Options oustanding and excersiable	500,000
Options granted August 5, 2015(2)
Options oustanding and excersiable	500,000
Options granted August 5, 2015(3)
Options oustanding and excersiable	500,000
Options granted August 5, 2015(4)
Options oustanding and excersiable	2,050,000

XML 49 R36.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Activity (Details) - shares	6 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	May 31, 2020	May 31, 2019
Details
Number of warrants outstanding	18,372,605		18,864,605	20,297,565
Warrants issued	988,000	6,050,000
Warrants exercised	0	7,482,960
Warrants expired	1,480,000

XML 50 R37.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Details (Details)	Nov. 30, 2020 shares
Number of warrants exercisable	18,372,605
Warrants Granted Mar 3 2016
Number of warrants exercisable	2,000,000
Warrants Granted Oct 12 2016
Number of warrants exercisable	9,094,605
Warrants Granted Feb 7 2018
Number of warrants exercisable	240,000
Warrants Granted June 24 2019
Number of warrants exercisable	3,950,000
Warrants Granted July 22 2019
Number of warrants exercisable	100,000
Warrants Granted Jan 29, 2020(1)
Number of warrants exercisable	1,000,000
Warrants Granted Jan 29, 2020(2)
Number of warrants exercisable	1,000,000
Warrants granted July 30, 2020
Number of warrants exercisable	988,000

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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